



**Steven Ribeiro Alves    A relevância da sinalização da insulina na doença de Alzheimer.**

**The relevance of insulin signalling in Alzheimer's disease.**



## DECLARAÇÃO

Declaro que este relatório é integralmente da minha autoria, estando devidamente referenciadas as fontes e obras consultadas, bem como identificadas de modo claro as citações dessas obras. Não contém, por isso, qualquer tipo de plágio quer de textos publicados, qualquer que seja o meio dessa publicação, incluindo meios eletrônicos, quer de trabalhos académicos.





**Steven Ribeiro Alves      A relevância da sinalização da insulina na doença de Alzheimer.**

**The relevance of insulin signalling in Alzheimer's disease.**

Dissertação apresentada à Universidade de Aveiro para cumprimento dos requisitos necessários à obtenção do grau de Mestre em Biologia Molecular e Celular, realizada sob a orientação científica da Professora Doutora Odete Abreu Beirão da Cruz e Silva, Professora Auxiliar com Agregação do Departamento de Ciências Médicas da Universidade de Aveiro.

Esta dissertação contou com o apoio financeiro do Instituto de Biomedicina (iBiMED) - UID/BIM/04501/2013 e PTDC/DTP-PIC/5587/2014 da Fundação para a Ciência e Tecnologia do Ministério da Educação e Ciência, programa COMPETE, do QREN e da União Europeia (Fundo Europeu de Desenvolvimento Regional).



Dedico este trabalho a toda a minha família pela educação, apoio e amor que me deram ao longo de todo este percurso.





## **o júri**

**Professora Doutora Maria de Lourdes Gomes Pereira**  
Professor Associado com Agregação, Universidade de Aveiro

**Professora Doutora Ana Gabriela da Silva Cavaleiro Henriques**  
Professora Auxiliar Convidada, Universidade de Aveiro

**Professora Doutora Odete Abreu Beirão da Cruz e Silva**  
Professora Auxiliar com Agregação, Universidade de Aveiro



## **Agradecimentos**

Gostaria de agradecer à Professora Doutora Odete da Cruz e Silva pela oportunidade de realizar este trabalho no laboratório de neurociências e sinalização celular e por toda a sua orientação, conselhos e encorajamento durante a realização desta dissertação.

À Professora Doutora Ana Gabriela Henriques pelo apoio e disponibilidade.

À Doutora Ilka Martins Rosa por ceder os dados epidemiológicos.

Ao Márcio pela orientação no laboratório e pela sua amizade, assim como ao João pela constante companhia.

A todos os meus colegas de laboratório pela ajuda, disponibilidade e companheirismo.

Aos meus amigos por facilitarem este longo percurso.

À Luísa por toda a compreensão e apoio incondicional durante todo este percurso.

E principalmente a toda a minha família por tornarem tudo isto possível e me apoiarem em tudo ao longo da minha vida.



## Palavras-chave

Doença de Alzheimer, Sinalização da insulina, resistencia à insulina, Tipo 2 Diabetes, APP, Tau, fosforilação.

## Resumo

A doença de Alzheimer (DA) é o tipo mais comum de demência no mundo. É caracterizada molecularmente pela deposição extracelular de placas senis (PS) compostas por agregados do péptido amiloide beta ( $A\beta$ ), pela formação de emaranhados neurofibrilares (EN) derivados da hiperfosforilação da proteína Tau, pela disfunção sináptica devido aos depósitos de PS e EN e também pelo stress oxidativo induzido pelo enfraquecimento das vias metabólicas.

A via de sinalização da insulina desempenha um papel principal em diversas vias da DA, tal como na clivagem da APP, hiperfosforilação da proteína Tau, eficiência da sinalização da insulina influenciada pela Apolipoproteína E (ApoE) e pela enzima envolvida na degradação de insulina que também é a enzima principal na degradação de  $A\beta$ .

Crescente evidência relaciona a DA com a diabetes de tipo 2 (T2D) devido ao mau funcionamento da sinalização pela insulina e da resistência cerebral à mesma. Num estudo baseado num cohort da região de Aveiro, foi observada uma correlação entre a diabetes e um mau resultado no teste do 'Mini Mental State Examination'. Adicionalmente, também foi observada uma correlação entre os portadores do alelo ApoE- $\epsilon$ 2 e um estado protetor contra a T2D. Este alelo também foi observado na literatura como sendo protetor contra a DA.

Posteriormente, uma análise de interações entre proteínas, identificou várias proteínas envolvidas tanto na DA como na sinalização da insulina. Correlacionando estes dados com o proteoma da sinapse, foi possível observar que existe uma grande representação das duas condições e também das proteínas coincidentes às duas (88% para a DA, 79% para a sinalização da insulina e 96% para as proteínas relacionadas com ambas), reforçando o papel de ambas as vias na sinalização e plasticidade sináptica. Do estudo de ontologia genética para a DA, foi possível identificar diversas vias importantes, tais como, resposta a um estímulo, organização de componentes celulares, comunicação celular, ligação proteica e ligação a uma cinase. Em relação à sinalização da insulina, as mesmas categorias apareciam com maior representação, significando que a insulina tem um papel importante em muitos eventos da DA. Por fim, o tratamento de SH-SY5Y diferenciadas com 0, 1, 10 e 100 nM de insulina por 0, 10 e 60 minutos mostraram uma diminuição nos níveis intracelulares da proteína Tau e um aumento na sua fosforilação na serina 396. Em relação à proteína precursora amiloide (APP), o tratamento de insulina levou a um aumento nos níveis intracelulares, quando exposta por 10 minutos seguido por uma diminuição aos 60 minutos. Quanto à fosforilação da treonina 668 da APP, foi previamente demonstrado que um aumento na fosforilação desse resíduo, promove a clivagem pela via amiloidogénica, levando à produção de  $A\beta$ . Nas células tratadas com insulina, um aumento claro da fosforilação desse resíduo da APP foi observado aos 10 minutos. Aos 60 minutos, os níveis da fosforilação eram baixos provavelmente devido aos baixos níveis de APP total.



## Keywords

Alzheimer's disease, Insulin signalling, Insulin resistance, Type 2 Diabetes, APP, Tau, phosphorylation.

## Abstract

Alzheimer's disease (AD) is the most common type of dementia worldwide. It is molecularly characterized by deposition of extracellular senile plaques (SPs) composed by aggregated amyloid beta ( $A\beta$ ) peptide, the formation of neurofibrillary tangles (NFTs) derived from hyperphosphorylation of the microtubule-associated protein Tau, synaptic dysfunction due to the deposits of SPs and NFTs and oxidative stress induced by impaired metabolic pathways.

The insulin signalling pathway can play a major role in diverse AD related pathways, such as APP cleavage, Tau hyperphosphorylation, Apolipoprotein E (ApoE) influence in insulin signalling efficiency and the insulin degrading enzyme, which is also the major  $A\beta$  degrading enzyme.

Growing evidence links AD with type 2 diabetes (T2D) due to impaired insulin signalling (IS) and brain insulin resistance. In a cohort based study in the Aveiro region, a correlation between diabetes and poor cognitive scores in the Mini Mental State Examination (MMSE) test were observed, with a p-value of 0.072. Additionally, carriers of the allele ApoE- $\epsilon$ 2 appeared to be protective against diabetes, in the literature the same allele appears to be protective for AD.

Posteriorly, the analysis of protein interactions, via the development of interactome networks, identified several proteins involved in both AD and the IS pathways. Also, by correlating these pathways with the synapse proteome, a very high overlap was observed (88% for AD, 79% for IS and 96% for AD and IS coincident proteins), enforcing the importance of both pathways in synaptic signalling and plasticity. From gene ontology studies, it was possible to assess the principal biological processes and molecular functions of the dataset of proteins. For AD, response to stimulus, cellular component organization, cell communication, signalling, protein binding, receptor binding and kinase binding were categories with elevated representation. Regarding coincident proteins between AD and IS pathways, an increase in all categories was observed, meaning that insulin plays a pivotal role in many AD events.

Finally, the analysis of SH-SY5Y differentiated cells treated with 0, 1, 10 and 100 nM of insulin for 0, 10 and 60 minutes, showed a decrease on the intracellular total levels of protein Tau and an increase in the phosphorylation at serine 396. Regarding the amyloid precursor protein (APP), increases in intracellular levels were observed, when treated with insulin for 10 minutes, followed by a decrease for 60 minutes exposure. The phosphorylation of APP at threonine 668, has previously been related to increased production of  $A\beta$ , by promoting APP cleavage via the amyloidogenic pathway. In cells treated with insulin, a clear increase was detected at the 10-minute time point. At 60 minutes, the levels of phosphorylation were low probably due to low total APP levels.





# Index

<b>I.</b>	<b>List of figures</b>	<b>III</b>
<b>II.</b>	<b>List of tables</b>	<b>V</b>
<b>III.</b>	<b>Abbreviations</b>	<b>VII</b>
1.	Introduction	1
1.1.	Characterizing Alzheimer's disease	1
1.1.1.	Amyloid precursor protein cleavage and amyloid $\beta$ production	1
1.1.2.	Hyperphosphorylation of microtubule-associated protein Tau	3
1.2.	Insulin signalling pathway	4
1.3.	Type 2 diabetes mellitus	6
1.4.	Insulin signalling pathway and Alzheimer's disease	6
1.4.1.	Insulin influence on APP cleavage	7
1.4.2.	Tau phosphorylation by GSK3 $\beta$	7
1.4.3.	APOE effect on insulin efficiency	8
1.4.4.	The role of the insulin degrading enzyme (IDE) in AD	8
2.	Objectives	13
3.	Materials and methods	17
3.1.	Epidemiological observation	17
3.2.	Network construction	18
3.3.	Neuronal cell models	20
3.3.1.	SH-SY5Y cell line	20
3.3.2.	SH-SY5Y cell culture	21
3.3.2.1.	Growth and maintenance of SH-SY5Y cell line	21
3.3.2.2.	Differentiation of SH-SY5Y cell line	22
3.3.2.3.	Insulin treatment	22
3.3.	Sample preparation and protein quantification	22
3.4.	Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)	23
3.5.	Western blot	24
4.	Results and discussion	29
4.1.	Diabetes correlates with poor cognitive scores	29
4.2.	Network analysis	31
4.2.1.	Key proteins interactomes	31
4.2.2.	Synapse network correlation	33
4.2.3.	Alzheimer's disease and insulin signaling pathway correlation	34
4.3.	SH-SY5Y differentiation	42
4.4.	Western blot analysis	44
4.5.	Resazurin assay analysis	49
5.	Conclusion	53
6.	References	57
7.	Appendix	65



## *I. List of figures*

Figure 1-- APP cleavage via the amyloidogenic and non-amyloidogenic pathway. ....	2
Figure 2- Tau phosphorylation sites and responsible kinases retrieved from AD brains. ....	4
Figure 3- Different actions of insulin when bound to the receptor. ....	5
Figure 4- Workflow for the study design.....	17
Figure 5 - APP interactome.....	31
Figure 6- Venn diagram of AD and IS proteins .....	38
Figure 7- All retrieved AD proteins. ....	39
Figure 8- Differentiation of SH-SY5Y cell line at different time points. ....	43
Figure 9- Total Tau levels in SH-SY5Y differentiated cells treated with insulin. ....	44
Figure 10- Tau phosphorylation at serine 396 in SH-SY5Y differentiated cells treated with insulin.. ....	45
Figure 11- Ratio between Tau phosphorylated at the serine 396 and total Tau.....	46
Figure 12- Total APP levels in SH-SY5Y differentiated cells treated with insulin.....	46
Figure 13- APP phosphorylation at threonine 668 in SH-SY5Y differentiated cells treated with insulin.. .	47
Figure 15 -Resazurin assay. ....	49



## *II. List of tables*

Table 1- Alzheimer's disease pathway key proteins .....	18
Table 2-Insulin signalling pathway key proteins .....	19
Table 3- BCA protein assay standards curve. ....	23
Table 4- Association of cognitive performance with comorbidities. ....	29
Table 5- Association of diabetes with cognitive evaluation and ApoE genotyping .....	30
Table 6 - AD proteins and the number of interactors involved .....	32
Table 7- IS proteins and the number of interactors involved .....	32
Table 8- Number and percentage of proteins involved in each pathway and in the synapse....	34
Table 9- Proteins identified as coincident in AD and the IS pathway. ....	35
Table 10- Biological process analysis of most relevant processes from AD proteins. ....	41
Table 11- Molecular function analysis of most relevant functions from AD proteins. ....	41
Table 12- Biological process analysis of most relevant processes from AD core proteins and only coincident proteins with IS pathway. ....	41
Table 13- Molecular function analysis of most relevant functions from AD core proteins and only coincident proteins with IS pathway. ....	42



### ***III. Abbreviations***

AD	Alzheimer's disease
ADL	Activities of Daily Living
AGE	Advanced glycation end-product
Akt/PKB	Protein kinase B
ApoE	Apolipoprotein E
APP	Amyloid precursor protein
A $\beta$	Amyloid beta
BBB	Blood-brain barrier
BCA	Bicinchoninic acid
BSA	Bovine serum albumin
CASP3	Caspase-3
CDK	Cyclin-dependent kinase
CDR	Clinical Dementia Rating
ChAT	Choline acetyltransferase
DM	Diabetes mellitus
DMSO	Dimethyl sulfoxide
ECL	Enhanced chemiluminescence
FBS	Fetal bovine serum
GDS	Global deterioration scale
GLUT4	Glucose transporter type 4
GO	Gene ontology
GRB2	Growth factor receptor-bound protein 2
GSK3	Glycogen synthase kinase 3
GSK3 $\beta$	Glycogen synthase kinase 3 $\beta$
IADL	Instrumental activities of daily living
IDE	Insulin degrading enzyme
IR	Insulin receptor
IRS	Insulin receptor substrate
IS	Insulin signalling
IU	International units
LB	Loading buffer
LTP	Long-term potentiation
MAP1B	Microtubule-associated protein 1B
MAPK	Mitogen-activated protein kinase
MAPT	Microtubule-associated protein Tau
MEM	Minimum essential medium
MMSE	Mini-Mental State Examination
mTOR	Mechanistic target of rapamycin
NCSTN	Nicastrin
NFTs	Neurofibrillary tangles
PBS	Phosphate buffered saline
Pcb-cohort	Primary care based cohort
PDPK	Proline-Directed Protein Kinase
PHF	Paired helical fragments
PI3K	Phosphoinositide 3-kinase
PIP2	Phosphatidylinositol 4,5-bisphosphate
PIP3	Phosphatidylinositol (3,4,5)-trisphosphate
PP1	Protein phosphatase 1
PSEN1	Presenilin-1
PSEN2	Presenilin-2

RA	Retinoic acid
S	Serine
SAP	Stress-activated protein
SDS-PAGE	Sodium dodecyl sulfate polyacrylamide gel electrophoresis
SOS	Son of Sevenless
SPs	Senile plaques
T	Threonine
T2D	Type 2 diabetes
TBS-T	Tris-buffered saline-tween
Y	Tyrosine



## **1.Introduction**



# 1. Introduction

## 1.1. Characterizing Alzheimer's disease

Alzheimer's disease (AD) is the most common type of dementia worldwide. It is estimated by the World Alzheimer Report of 2015 that 46.8 million people suffer from dementia and that this number will duplicate every 20 years.<sup>1</sup>

AD is a progressive disease characterized by a deterioration of memory and cognitive functions that can lead to death in 3 to 9 years after diagnosis.<sup>2</sup> In early stages of the disease, almost no symptoms occur, but in late-stages, there is complete loss of autonomy and no response to the environment. No cure is available for AD or other type of dementia, although some drugs can delay disease progression.<sup>3</sup>

Brain changes in AD can begin many years before symptom onset, but there is no efficient early diagnosis. Nevertheless, some possible risk factors have been described such as age, the presence of certain alleles of genes (particularly apolipoprotein E – ApoE-ε4)<sup>4,5</sup>, gender (female)<sup>6</sup>, low education levels<sup>7</sup>, head trauma<sup>8</sup>, small hippocampal volume<sup>6</sup>, insulin resistance<sup>9</sup>, high cholesterol, hypertension, reduced exercise and obesity<sup>5</sup>.

The molecular mechanisms of the disease have been studied for many years and principal hallmarks have been well described. Amongst them the accumulation of extracellular senile plaques (SPs) caused by the deposition and aggregation of the peptide amyloid β (Aβ) which arises as a result of amyloid precursor protein (APP) cleavage<sup>10,11</sup>; the formation of neurofibrillary tangles (NFTs) derived from hyperphosphorylation of the microtubule-associated protein Tau<sup>12,13</sup> ; synaptic dysfunction due to the deposits of SPs and NFTs and the oxidative stress induced by impaired metabolic pathways<sup>14</sup>.

### *1.1.1. Amyloid precursor protein cleavage and amyloid β production*

The amyloid precursor protein (APP) is a transmembrane protein found in many tissues, and is targeted to the synapses of neurons. The precise function of APP is unknown, but some assumptions are possible. Mice with deficient APP show many phenotypes including reduced body and brain size, impaired learning and long-term potentiation (LTP) and hypersensitivity to seizures<sup>15</sup>. Thus it would appear that APP has an important role in memory associated events. At a cellular level, studies employing wild-type APP overexpression in transfected cell lines showed

improved cell growth, motility, neurite outgrowth and cell survival<sup>16</sup>. Thus APP, and APP derived fragments have been attributed with growth factor related characteristics.

APP processing is achieved by cleavage at specific sites and performed by specific proteolytic enzymes. APP can be cleaved by two different pathways, the amyloidogenic pathway and the non-amyloidogenic pathway. In the non-amyloidogenic pathway, APP is cleaved by  $\alpha$  and  $\gamma$ -secretase, originating sAPP $\alpha$  and the peptides P3 and AICD (Figure 1). P3 is not toxic to the neurons and can be rapidly degraded<sup>17</sup>. On the other hand, in the amyloidogenic pathway, APP is cleaved by  $\beta$  and  $\gamma$ -secretase, originating sAPP $\beta$  and the peptides A $\beta$  and AICD. The excess of A $\beta$ , which aggregates as SPs, is one of the major contributors to the degeneration and dysfunction of neurons in AD<sup>18</sup>.




Figure 1-- APP cleavage via the amyloidogenic and non-amyloidogenic pathway. Secreted products obtained in the two pathways are indicated. Taken from: <sup>19</sup>

### *1.1.2. Hyperphosphorylation of microtubule-associated protein Tau*

The protein Tau is expressed abundantly in the axons of neurons in the central nervous system, but can also be found in many others cells. This protein's most important role is to promote stability and assembly of microtubules, although this function can be complemented by other proteins, especially microtubule-associated protein 1B (MAP1B)<sup>20</sup>, suggesting that Tau protein is not vital. Indeed, Tau knockout mice are viable, fertile, normal and show no signs of neurodegeneration. Complementing, knock out of Tau by small interfering RNA in primary neurons did not cause death, nor did it prevent axon formation and growth<sup>21</sup>.

In AD, abnormal Tau phosphorylation and aggregation plays an important role in pathogenesis, forming intracellular neurofibrillary tangles (NFTs) that lead ultimately to cell death<sup>22</sup>. In the hyperphosphorylated state, Tau sequesters normal Tau and other proteins associated to microtubules, leading to microtubule destabilization and polymerization. Consequentially, axonal transport and neurotransmission are compromised, affecting cognitive functions. The major group of proteins involved in Tau phosphorylation are the proline-directed protein kinases (PDPK) that include glycogen synthase kinase 3 (GSK3), mitogen activated protein kinase (MAPK), Tau-tubulin kinase, cyclin-dependent kinase (principally CDK2 and CDK5) and stress-activated protein kinases (SAP kinases). In Tau extracted from AD patient brains, 45 phosphorylation sites (Figure 2) were discovered (29 serines (S), 13 threonines (T) and 3 tyrosines (Y)), of which, the majority can be phosphorylated by GSK3 $\beta$ , making this kinase, one of the most relevant in Tau hyperphosphorylation<sup>13,23</sup>.




Figure 2- Tau phosphorylation sites and responsible kinases retrieved from AD brains. S- Serine, T- Threonine and Y- Tyrosine. Microtubule – binding domain is indicated \*\*\*. Taken from:<sup>13</sup>

## 1.2. Insulin signalling pathway

Insulin controls extensive biological processes by acting on a tyrosine kinase receptor. Receptor activation initiates a cascade of events involving phosphorylation, leading to activation or inactivation of many enzymes that control many physiological functions, namely metabolism and growth. Perturbations in the cascades can lead to insulin resistance<sup>24</sup>.

Insulin's main actions are to stimulate the uptake of glucose and glycogen synthesis but it is also able to regulate many biological processes such as increased amino acid uptake, increased lipid synthesis, and decreased lipolysis, among others depending on the type of cells<sup>25</sup>.

Many proteins are phosphorylated and dephosphorylated in the cascade of events when insulin binds to its receptor. Insulin and insulin receptor (IR) binding, results in a conformational change that induces the autophosphorylation of many tyrosine residues in the receptor<sup>26</sup>. The insulin receptor substrate family (IRS) recognizes these residues, which are, in turn, recognized by the phosphoinositide 3-kinase (PI3K). PI3K has the ability to phosphorylate phosphatidylinositol 4,5-bisphosphate (PIP2) into phosphatidylinositol (3,4,5)-trisphosphate (PIP3) and in the presence of phosphoinositide-dependent kinase-1 leads to the phosphorylation and activation of protein kinase B (PKB, also known as AKT). The activation of AKT is necessary for the regulation of many processes,

such as recruitment of Glucose transporter type 4 (GLUT4) to the membrane for glucose entrance, inhibition of GSK3 $\alpha$  and  $\beta$ , resulting in glycogen synthesis and activation of the mammalian target of rapamycin (mTOR), which promotes protein synthesis<sup>27</sup>(Figure 3). The binding of insulin to the IR, also triggers a second pathway, that leads to growth factor receptor-bound protein 2 (GRB2) activation, which in turn associates with the guanine nucleotide exchange factor son-of sevenless (SOS) leading to the activation of the mitogen-activated protein kinases (MAPK) pathway<sup>28</sup>. The activation of the MAPK pathway promotes cell division and differentiation.

It has only been a few years since the brain was considered as an insulin-sensitive organ. This was achieved by the detection of insulin and insulin receptors in the brain, although the origin of the insulin is still in debate. Its origin has been explained as deriving from peripheral or central sources, or even both. The discovery of insulin mRNA in the brain proved that it could be produced in the brain<sup>29,30</sup>. On the other hand, it was also shown that insulin can cross the blood-brain barrier (BBB) using a receptor mediated transport system<sup>29–31</sup>. Recent studies demonstrated that insulin regulates brain glucose and lipid metabolism, but it also regulates neuronal activities and development, playing an important role in learning and memory<sup>30</sup>.




Figure 3- Different actions of insulin when bound to the receptor. Adapted from: <sup>32</sup>

### 1.3. Type 2 diabetes mellitus

Type 2 diabetes mellitus (T2D) is a metabolic disorder that is characterized mainly by an elevation of glucose in the blood due to insulin resistance. This disease accounts for 90% of all cases of diabetes and is in exponential growth, as of 2014 records show that 422 million adults worldwide have T2D in comparison with only 108 million in 1980. Some people may be genetically predisposed to contract T2D<sup>33</sup>, however this disease occurs mainly as a result of obesity and lack of exercise<sup>34</sup>. This condition is mainly controlled with the administration of metformin, leading to a decrease in glucose production by the liver and an increase in insulin sensitivity of body tissues<sup>35</sup>.

Many factors can molecularly lead to insulin resistance. The most common include a decrease in the number of insulin receptors and of their catalytic activity, an increased Ser/Thr phosphorylation of the IR or the IRS, increase in tyrosine phosphatase activity, a decrease in PI3K and Akt kinase's activities and defective GLUT4 expression and/or function. These molecular changes lead to defective metabolism and a defective insulin cascade of events<sup>36</sup>.

### 1.4. Insulin signalling pathway and Alzheimer's disease

In 1970 S. Hoyer reported reduced glucose levels and lower cerebral metabolic rates in the brains of demented individuals<sup>37</sup>. Today we know that many pathologies exhibit diminished brain glucose absorption, among them AD, Parkinson's disease, Multiple sclerosis, Huntington's Disease, Duchenne muscular dystrophy, forms of Autism, Down's Syndrome and Type I and Type II Diabetes Mellitus. The risk of developing AD is 50-60% greater in individuals with T2D<sup>38</sup>. Consistently, rats injected with streptozotocin intracerebroventricularly exhibit decreased glucose/energy brain metabolism and learning and memory deficits<sup>39</sup>.



#### *1.4.1. Insulin influence on APP cleavage*

APP is one of the main proteins associated with AD. It is not known how the cell determines the pathways via which APP is processed. However insulin can play a major role in APP processing, promoting the non-amyloidogenic pathway. In a recent study, it was demonstrated that in the SH-SY5Y cell line insulin increased the levels of ADAM10 ( $\alpha$ -secretase) and decreased those of BACE1 ( $\beta$ -secretase), leading to a decrease in A $\beta$  production. Consistently, disturbances in the insulin cascade of events can be related with increases in A $\beta$  production<sup>40</sup>.

#### *1.4.2. Tau phosphorylation by GSK3 $\beta$*

Glycogen synthase kinase-3  $\beta$  (GSK3 $\beta$ ) is a proline-directed serine/threonine kinases, expressed ubiquitously and involved in many cellular processes, namely glycogen metabolism<sup>41</sup>, gene transcription<sup>42</sup>, apoptosis<sup>43</sup> and microtubule stability<sup>44,45</sup>.

This kinase is under close regulation of insulin and protein phosphatase 1 (PP1), both with the capacity to inactivate it. Phosphorylation of GSK3 $\beta$  at serine 9 by insulin turns the kinase inactive while PP1 has the ability to dephosphorylate the tyrosine 216 leading to the same inactive state<sup>46</sup>.

In AD post mortem brain analysis, the values of PP1 appear diminished, leading to an increase activation of GSK3 $\beta$ . In the PC12 cell line, the presence of A $\beta$  inhibited PP1<sup>47</sup>, leading to hyperphosphorylated protein Tau, probably through dysregulation of GSK3 $\beta$ .

In T2D, deregulation in the insulin signalling (IS) pathway can also lead to GSK3 $\beta$  activation. Taken together, the deregulation of IS pathway and the inhibition of PP1 lead to a constant activation of this protein, continuously phosphorylating its substrates, namely protein Tau.

### *1.4.3. APOE effect on insulin efficiency*

Apolipoprotein E (ApoE), in the brain, can be produced by both glia and neurons and its major role is to redistribute lipids among cells in the brain<sup>48,49</sup>. ApoE has 3 distinctive alleles (ApoE- $\epsilon$ 2, ApoE- $\epsilon$ 3 and ApoE- $\epsilon$ 4), with ApoE- $\epsilon$ 4 occurring in more than 50% of AD cases<sup>49</sup>.

Clinical data showed that intranasal administration of insulin improved performance in learning and memory of elderly individuals. This performance is also correlated with the plasma levels of APP<sup>50–52</sup>. On the other hand, these effects are ApoE isoform dependent, where ApoE- $\epsilon$ 4 carriers showed no improvement in memory tasks or no reduction of APP plasma levels<sup>51,53</sup>.

A recent study in mice showed that insulin signalling impairment in the presence of A $\beta$  was specific of ApoE genotype. The expression of ApoE- $\epsilon$ 4 led to reduced insulin stimulation while ApoE- $\epsilon$ 2 and 3 had preventive measures against A $\beta$ , inducing proper insulin signalling<sup>54</sup>.

These results are concurrent with another study that demonstrated that intranasal administration of 20 and 40 international units (IU) of insulin improved verbal memory of AD subjects, but only for those without the ApoE- $\epsilon$ 4 allele<sup>51</sup>.

### *1.4.4. The role of the insulin degrading enzyme (IDE) in AD*

IDE, insulin degrading enzyme, is responsible for degrading insulin, however it is also the major enzyme responsible for degrading A $\beta$ . Although IDE is elevated in AD brains, this does not translate into a higher A $\beta$  clearance. On the contrary, IDE has more affinity for insulin than A $\beta$ , which will lead to a higher degradation of insulin than normal causing a lower glucose metabolism. Hence insulin increases extracellular A $\beta$  levels by promoting its secretion, but also by inhibiting its degradation via IDE. It is particularly noteworthy that IDE degrades A $\beta$  in both microglial and neuronal cultures<sup>55,56</sup> and some APP isoforms are common to leucocytes and microglia, the LAPPs. Given that insulin resistance arises via a negative feedback loop of the insulin receptor pathway, this occurs under conditions of high insulin. The response involves the PI3I/AKT pathway (among others) as well as the insulin receptor substrates (IRSs). It is expected that induction of IDE will prevent the negative feedback and lower circulating insulin<sup>57,58</sup>.

Many other cellular and molecular aspects are common to T2D and AD, these include  $\text{Ca}^{++}$  mediated signalling, formation of AGE (advanced glycation end-products), Wnt/ $\beta$ -catenin signalling, ChaT (ChAT, acetylcholine transferase) and JNK (c-Jun N-terminal kinase) mediated responses, these are beyond the scope of this project. It follows that the disease specific interactomes will unravel the involvement of several pathways, relevant to AD and T2D.

It would appear that a common pathophysiology in T2D and AD is becoming evident. Both conditions have a higher incidence with ageing and patients with T2D have a greater risk of developing AD. Hyperinsulinaemia and insulin resistance contribute to memory impairment and AD is increasingly perceived as also a metabolic disorder. The AD brain loses the capacity to: utilize glucose efficiently; respond to critical trophic factor signals and develops resistance to insulin and insulin growth factor (IGF). Glucose is the main brain energy source; these anomalies cause the brain to 'starve' accounting for AD associated abnormalities. Thus the term Type 3 diabetes (T3D) has been coined for AD. In closing, individuals with T2D have a higher risk of developing AD, but the cellular mechanisms remain unknown. Of concern diabetes medication could increase dementia risk. Metformin, prescribed for T2D, increases BACE1 levels and  $\text{A}\beta$  production, propagating AD progression. On a more positive note, insulin in combination with metformin may override the BACE1 effect and be beneficial to T2D+AD (T3D) patients<sup>59</sup>. Thus, it is fundamental to unravel the underlying cellular signalling cascades that can contribute to patient management and well-being.



## **2.Objectives of the study**



## 2. Objectives

The main goal of this work is to determine if a correlation between Alzheimer's disease and type 2 diabetes at a clinical level, exists. For this purpose, it is necessary to explore different tools in order to unravel molecular mechanisms behind the two conditions, such as statistical population studies, bioinformatics and also molecular mechanisms.

Thus the specific objectives are to:

- Address if there is an association between cognitive capacities and diabetes;
- Unravel interactome networks relevant to AD and Insulin signalling;
- Optimize conditions for differentiating a neuronal-like cell line;
- Determine the effect of insulin on AD relevant molecules.





### **3.Materials and methods**



### 3. Materials and methods

#### 3.1. Epidemiological observation

A cross-sectional population-based survey was previously carried out on a Portuguese population, in the Aveiro district<sup>60</sup>. Volunteers were admitted, independent of complaints or deficits in any cognitive domain. A mandatory inclusion criteria to be 50 years or older was observed. Individuals undergoing oncological treatment, diagnosed with psychiatric disorders (excluding depression), aphasia, or unable to answer the questions in the structured interview were excluded. To ensure generalizability, exclusion criteria were kept to an absolute minimum. Participants underwent a semi-structured questionnaire addressing sociodemographic characteristics, personal and family history. Subsequently questions typically associated with diagnosing dementia were asked. Clinical history and medications taken were collected from clinical records and registered. The study group was designated the primary care based cohort, pcb-Cohort.



Figure 4- Workflow for the study design.

Cognitive evaluations and dementia screening tests, irrespective of the clinical diagnosis, were performed during the interview. These included Clinical Dementia Rating (CDR)<sup>61</sup>, Mini Mental State Examination (MMSE), Geriatric Depression Scale (GDS)<sup>62</sup>, Katz of Activities of Daily Living (ADL)<sup>63</sup> and Instrumental Activities of Daily Living (IADL)<sup>64</sup>. The tests CDR, MMSE, GDS and IADL had been previously standardize for the Portuguese population<sup>65</sup>. Participants were also scored for comorbidities, including diabetes. Volunteers were recruited in primary health centers (pcb-Cohort) in the Aveiro region.

### 3.2. Network construction

The protein networks were built based on protein-protein interactions that are found on the available literature, relevant to Alzheimer's disease (AD) and Insulin signalling (IS) pathways. The first step was to determine the key proteins (table 1 and 2) in order to build the interactome for each of these proteins. These key proteins were determined using KEGG pathway, for both pathways.

*Table 1- Alzheimer's disease pathway key proteins*

Gene name	Uniprot code	Protein complete name
APOE	P02649	Apolipoprotein E
APP	P05067	Amyloid beta A4 protein
BACE1	P56817	Beta-secretase 1
MAPT / TAU	P10636	Microtubule-associated protein tau
PSEN1	P49768	Presenilin-1
PSEN2	P49810	Presenilin-2
ADAM10	O14672	Disintegrin and metalloproteinase domain-containing protein 10
ADAM17	P78536	Disintegrin and metalloproteinase domain-containing protein 17
APH1A	Q96BI3	Gamma-secretase subunit APH-1A (Presenilin-stabilization factor)
APH1B	Q8WW43	Gamma-secretase subunit APH-1B
CAPN1	P07384	Calpain-1 catalytic subunit
CAPN2	P17655	Calpain-2 catalytic subunit
CASP3	P42574	Caspase-3
CASP7	P55210	Caspase-7
CDK5	Q00535	Cyclin-dependent-like kinase 5
CDK5R1	Q15078	Cyclin-dependent kinase 5 activator 1
IDE	P14735	Insulin-degrading enzyme
LPL	P06858	Lipoprotein lipase
LRP1	Q07954	Prolow-density lipoprotein receptor-related protein 1
MME/NEP	P08473	Neprilysin
NCSTN	Q92542	Nicastrin
PSENEN	Q9NZ42	Gamma-secretase subunit PEN-2
RTN3	O95197	Reticulon-3
RTN4	Q9NQC3	Reticulon-4

Table 2-Insulin signalling pathway key proteins

Gene name	Uniprot code	Protein complete name
AKT1	P31749	RAC-alpha serine/threonine-protein kinase
AKT2	P31751	RAC-beta serine/threonine-protein kinase
AKT3	Q9Y243	RAC-gamma serine/threonine-protein kinase
GLUT4/SLC2A4	P14672	Solute carrier family 2, facilitated glucose transporter member 4
GRB2	P62993	Growth factor receptor-bound protein 2
GSK3A	P49840	Glycogen synthase kinase-3 alpha
GSK3B	P49841	Glycogen synthase kinase-3 beta
INSR	P06213	Insulin receptor
IRS1	P35568	Insulin receptor substrate 1
IRS2	Q9Y4H2	Insulin receptor substrate 2
MAPK1	P28482	Mitogen-activated protein kinase 1
MAPK3	P27361	Mitogen-activated protein kinase 3
PIK3CA	P42336	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
PIK3CB	P42338	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
PIK3CD	O00329	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
PIK3R1	P27986	Phosphatidylinositol 3-kinase regulatory subunit alpha
PIK3R2	O00459	Phosphatidylinositol 3-kinase regulatory subunit beta
PIK3R3	Q92569	Phosphatidylinositol 3-kinase regulatory subunit gamma
PDPK1	O15530	3-phosphoinositide-dependent protein kinase 1
SOS1	Q07889	Son of sevenless homolog 1
SOS2	Q07890	Son of sevenless homolog 2
HRAS	P01112	GTPase HRas
KRAS	P01116	GTPase KRas
NRAS	P01111	GTPase NRas
ARAF	P10398	Serine/threonine-protein kinase A-Raf
RAF1	P04049	RAF proto-oncogene serine/threonine-protein kinase
BRAF	P15056	Serine/threonine-protein kinase B-raf
MAP2K1	Q02750	Dual specificity mitogen-activated protein kinase kinase 1
MAP2K2	P36507	Dual specificity mitogen-activated protein kinase kinase 2
MTOR	P42345	Serine/threonine-protein kinase mTOR
BAD	Q92934	Bcl2-associated agonist of cell death
FOXO1	Q12778	Forkhead box protein O1

Posteriorly, the uniprot code for the *Homo sapiens* of each of the key proteins was retrieved (Table 1 and 2), in order to eliminate interactions described in other species, and were submitted into the IntAct Molecular Interaction Database. Different databases (IntAct, String and BioGRID) were tested and IntAct demonstrated to be more complete and reliable, as well as including only curated data.

All data recovered from IntAct were imported to Cytoscape and the interaction networks were built for each protein.

In order to get the interactome for the AD pathway and the IS pathway, the interactomes of each protein from each pathway were merged and organized for better visualization. Also, the list of all protein interactions of each pathway were crossed so as to identify coincident proteins. These were marked in a different colour in the network.

Also a network for the synapse was built. All synaptic proteins were obtained by a Gene Ontology (GO\_0045202) predefined list already assembled in the literature.

### 3.3. Neuronal cell models

The use of human in vitro neuronal cell models has been fundamental to understand the functioning of the nervous system. Cell models play an important role in reducing animal testing and provide a better understanding of human cells, because of the identical genome.

The culture of neuronal cells is hard to achieve, since mature neurons do not undergo significant cell division. For this purpose, it is necessary to use cell lines that are derived from neuronal tumours and have become immortalized. These cells are easier to grow and present small variability between cultures.

#### 3.3.1. *SH-SY5Y cell line*

SH-SY5Y (ATCC® CRL-2266™) cell line are a subclone of the neuroblastoma cell line SK-N-SH. This cell line was generated from a bone marrow biopsy in 1970. It is composed of two types of cells: neuroblast-like and epithelial-like. The SH-SY5Y cell line can be differentiated into a neuronal mature human state through different mechanisms, depending on the neuron subtype required (adrenergic, cholinergic or dopaminergic). This cell line has been extensively used as a neuronal cell model due to the resemblance to primary neurons.

Both differentiated and non-differentiated SH-SY5Y cells are used in in-vitro experiments, depending on the target in study. Undifferentiated cells tend to grow in clusters and are morphologically neuroblast-like with non-polarized cell bodies. They also lack mature neuronal

markers. In contrast, differentiation into neuronal-like cells leads to different events, including the induction of neuron-specific enzymes, neurotransmitter and neurotransmitter receptors, formation and extension of neuritic processes, synaptophysin-positive functional synapses and increased electrical excitability of the plasma membrane. Thus for this reason we opted to differentiate the SH-SY5Y cell line and use it in subsequent experiments.

### *3.2.2. SH-SY5Y cell culture*

#### *3.2.2.1. Growth and maintenance of SH-SY5Y cell line*

The complete growth medium used to maintain this cell line is composed of a 1:1 mixture of Eagle's Minimum Essential Medium (MEM) and F12 supplemented with 10% of heat-inactivated Fetal Bovine Serum (FBS), 2nM L-Glutamine, sodium bicarbonate, sodium pyruvate and 1% of antibiotic/antimycotic.

Prior to use, cells were cryopreserved in liquid nitrogen at -196°C with a cell freezing medium composed by complete growth medium supplemented with 5% (v/v) dimethyl sulfoxide (DMSO).

To use, cells were quickly thawed to 37°C, 1ml of cell media was added to the vial and centrifuged at 1000 rpm for 3 minutes to remove the DMSO. The pellet of cells was re-suspended in fresh complete growth medium and seeded in a 100mm culture plate.

Cell cultures were maintained in an incubator at 37°C with 5% CO<sub>2</sub> and 95% humidity. Every three days, complete growth medium was replaced until cell splitting. To split the cells, all medium was aspirated and cells were washed with 2 ml of pre-warmed Phosphate Buffered Saline (PBS). Afterwards, the PBS was aspirated and 2ml of 0,05% of Trypsin-EDTA solution was added to re-suspend adherent cells. After cell detachment, 6ml of fresh complete growth medium was added to inactivate the trypsin, followed by centrifugation at 1000 rpm for 3 minutes in a 15ml vial. Finally, the supernatant was carefully discarded, cells were re-suspended in fresh medium and plated at the desired cell density.

#### 3.2.2.2. *Differentiation of SH-SY5Y cell line*

The differentiation of this cell line is mainly achieved by the addition of Retinoic Acid (RA) to the complete growth medium.

The literature offers many options for the differentiation of the SH-SY5Y cell line, a protocol optimization was necessary to test the optimal conditions. For this, the most important variables on the protocols was the percentage of fetal bovine serum (FBS) used and the time of exposure to the RA. Four hundred thousand cells were plated in each well of a 6-well plate (diameter 34.8 mm) and two concentrations of FBS (1% and 10%) were tested in combination with 10  $\mu$ M of RA. Phase-contrast photographs were taken at day 0, 3 and 5, and cell elongation and neurites outgrowth were assessed.

#### 3.2.2.3. *Insulin treatment*

Human insulin was obtained from Sigma-Aldrich (product code I3536) and reconstituted in PBS. To test the influence of insulin, cells were exposed to 0, 1, 10 and 100 nM of insulin in combination with serum free medium for 0, 10 and 60 minutes at 37°C.

### 3.3. Sample preparation and protein quantification

After treatments, cells were washed with ice-cold PBS and then collected using RIPA lysis buffer (Sigma, cat. #R0278) and a cocktail with protease and phosphatase inhibitor (cOmplete, EDTA-free, Roche, cat. #11873580001). Subsequently, lysates were sonicated during 10 seconds and stored at -20°C.

Protein quantification was obtained using bicinchoninic acid (BCA) assay, using Pierce™ BCA Protein Assay kit (Thermo Fisher Scientific, cat. #23225). This assay relies on two different reactions. Initially, the ability of peptide bonds to reduce  $\text{Cu}^{2+}$  to  $\text{Cu}^+$ . The amount of  $\text{Cu}^{2+}$  reduced is proportional to the amount of protein in the sample. This reaction is followed by the chelation of



molecules of BCA to one molecule of  $\text{Cu}^+$  forming a purple-coloured complex exhibiting a strong absorbance at 562 nm.

In order to determine the precise amount of protein in the sample, it is necessary to use a standard where the amount of protein is previously known as described in the table 3.

*Table 3- Standards used in BCA. Bovine Serum Albumin (BSA).*

Standard	BSA ( $\mu\text{L}$ )	Buffer ( $\mu\text{L}$ )	Protein mass ( $\mu\text{g}$ )
P0	-	25	0
P1	1	24	2
P2	2	23	4
P3	5	20	10
P4	10	15	20
P5	20	5	40

For protein quantification, 5  $\mu\text{L}$  of SH-SY5Y lysates were used. Standards and samples were incubated with 200  $\mu\text{L}$  of working reagent previously prepared by adding 50 parts of reagent A and 1 part of reagent B from the Pierce™ BCA Protein Assay kit. The plate was incubated for 30 minutes at 37°C and the absorbance was immediately measured at 562nm using TECAN Infinite M200.

### 3.4. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)

SDS-PAGE is used to separate proteins from a mixture based on molecular weight. This technique relies on the capacity of proteins to migrate through gel pores under an electrical field. SDS needs to be used in this method to remove different protein charges and in order to charge negatively all proteins, enabling the sample to migrate from a negative to a positive pole. A reducing agent ( $\beta$ -mercaptoethanol) is also used in combination with SDS to dissociate proteins before loading the gel. This ensures that all disulphide bonds are cleaved, linearizing the proteins so that the tertiary and quaternary protein structures do not interfere with the migration in the gel.

In this work, samples were subjected to 5-20% gradient SDS-PAGE in a Hoefer electrophoresis system. The gel is composed of 2 phases, the stacking gel, where the samples are loaded, and the resolving gel, where the proteins are separated. The resolving gel has a linear progression in the concentration of acrylamide from top to bottom, in order to get a wider separation range.

Firstly, the resolving gel solution was prepared and carefully pipetted into the mounted electrophoresis equipment and distilled water added on top to reduce toxicity to the environment. The gel was left for 1h at room temperature in order to polymerize. Subsequently, the stacking gel solution was prepared, the water from the equipment was poured out and the solution loaded on top of the running gradient gel. A comb was inserted to mark the wells for the samples and the gel was left a further 1 hour to polymerize at room temperature.

In parallel, samples were prepared by adding to the protein sample solution,  $\frac{1}{4}$  volume of 4X loading buffer (LB) and boiled for 10 minutes. The samples and the molecular weight marker (Precision Plus Protein™ Dual Color Standards, Bio Rad, cat. #1610374) were then carefully loaded into the wells and separated by electrophoresis at 90 mA of electric current for 3 to 4 hours.

### 3.5. Western blot

Western blot or Immunoblot is a widely used technique for detection and analysis of proteins. This technique is used to detect specific proteins in complex samples like cell lysates or body fluids. Following the SDS-PAGE, the proteins are transferred to a solid membrane, in this case, a nitrocellulose membrane, by an electrophoretic field while the proteins positions remain unaltered. Once in the membrane, proteins are suitable for detection by protein staining or labelling by specific antibodies. The membranes can be stained with Ponceau S, to confirm protein transfer and assess equal gel loading. Before incubating with antibodies, the membranes need to be blocked with either non-fat milk or BSA, in order to block non-specific sites of the primary antibody. Membranes are then incubated with the specific primary antibody followed by the secondary antibody. After the binding, the antibodies can be detected by chemiluminescence and detected using appropriate equipment.

Transfer was confirmed by Ponceau staining. Ponceau S is a dye that binds to protein positive amino acids and to non-polar protein regions in a non-covalent form. For this purpose, the

membrane was hydrated with Tris-buffered saline solution (TBS) during 10 minutes under agitation, followed by the ponceau staining solution for 5 minutes. After the incubation, the solution was removed from the membrane using deionized H<sub>2</sub>O to remove the excess.

After confirming the transfer and totally removing ponceau staining, membranes were blocked with 5% BSA in tris buffered saline tween (TBS-T) 1x for 4 hours. The membranes were subsequently washed in TBS-T 1x for 10 minutes and incubated with a specific primary antibody overnight. In the next morning, membranes were washed six times with TBS-T 1x for 10 minutes each and incubated with the appropriated secondary antibody for 2h. Following the incubation, the membranes were washed six times with TBS-T 1x for 10 minutes each and incubated with enhanced luminescence (ECL) detection kit for 5 minute, followed by visualization of the membrane using ChemiDoc Imaging System.

### 3.6. Resazurin assay

Resazurin is a cell permeable redox indicator that can be used to monitor cell viability. Resazurin is a blue dye that can be dissolved in physiological buffers or cell culture medium. Cells with active metabolism can reduce resazurin into resorufin, which is pink and fluorescent. The quantity of resorufin that is produced is proportional to the number of viable cells which can be quantified using a microplate equipped with fluorimeter with a 560 nm excitation and 590 nm emission filter set.

For this assay, differentiated SH-SY5Y cells were pre-treated with different concentrations of insulin (0, 1, 10 and 100 nM) for 0, 10 and 60 minutes, followed by incubation with 10 µg/ml of resazurin for 4 hours.



## **4.Results and Discussion**



## 4. Results and discussion

### 4.1. Diabetes correlates with poor cognitive scores

The MMSE was applied to the pcb-Cohort and scored from 0-30. Cut-off was set at  $\geq 7$  years of literacy and MMSE cut-off at 27 <sup>66</sup>. Those equal to or below the cut-off are scored as having cognitive deficit, those above the cut-off as normal. Individuals were also analyzed with respect to comorbidities (Table 4). A positive correlation with neuropathological disorders was obtained for the three MMSE cut-off analyses (Table 4). In effect one can confirm that the diagnosis of neuropathological conditions was correct in this population. With respect to other comorbidities the strongest correlation was obtained with diabetes (DM) and MMSE 27 with a p-value of 0.072 (Table 4).

Table 4- Association of cognitive performance with comorbidities. Taken from:<sup>67</sup>

Clinical Characteristic	N	MMSE Cut Point 27		
		Negative (N=436)	Positive (N=132)	p-value
Number of Disease	-	2.98 $\pm$ 1.68 <sup>a</sup>	3.11 $\pm$ 1.68 <sup>a</sup>	0.466
Hyp*	351	265 <sup>a</sup> (60.8%)	86 <sup>a</sup> (65.2%)	0.365
Dys*	333	257 <sup>a</sup> (58.9%)	76 <sup>a</sup> (57.6%)	0.780
OA*	305	227 <sup>a</sup> (52.1%)	78 <sup>a</sup> (59.1%)	0.156
CVD*	302	234 <sup>a</sup> (53.7%)	68 <sup>a</sup> (51.5%)	0.664
Dep*	182	136 <sup>a</sup> (31.2%)	46 <sup>a</sup> (34.8%)	0.430
GID*	151	112 <sup>a</sup> (25.7%)	39 <sup>a</sup> (29.5%)	0.379
GUD*	122	98 <sup>a</sup> (22.5%)	24 <sup>a</sup> (18.2%)	0.292
DM*	115	81 <sup>a</sup> (18.6%)	34 <sup>a</sup> (25.8%)	<b>0.072</b>
Resp*	93	70 <sup>a</sup> (16.1%)	23 <sup>a</sup> (17.4%)	0.710
Hemato*	60	46 <sup>a</sup> (10.6%)	14 <sup>a</sup> (10.6%)	0.985
Onco*	32	26 <sup>a</sup> (6.0%)	6 <sup>a</sup> (4.5%)	0.536
Neuro*	22	9 <sup>a</sup> (2.1%)	13 <sup>b</sup> (9.8%) <sup>b</sup>	<b>&lt;0.001</b>
Alc*	14	9 <sup>a</sup> (2.1%)	5 <sup>a</sup> (3.8%) <sup>a</sup>	0.263

Additionally the correlation of diabetes with other factors was also evaluated. The CDR applied a 0 to 3 score <sup>61</sup>, where 0=Normal, 0.5=suspect, questionable or very mild dementia, and CDR $\geq$ 1(1, 2, 3)=mild, moderate or severe dementia. The reduced GDS was also applied, version GDS-15 <sup>62</sup>. Results were scored from 0-15, where 0-4 is normal and above 5 is consistent with depression. IADL was applied to evaluate eight daily functionalities <sup>64</sup>. Results are shown in table 5.

Table 5- Association of diabetes with cognitive evaluation and ApoE genotyping

Characteristics	N(%)	Diabetes Mellitus		Statistical test	p-value
		No N= 453	Yes N= 115		
Cognitive Evaluation					
MMSE27	132 (23,2%)	98 (21,6%)	34 (29,6%)	$\chi^2= 3.325$	0.072
CDR ≥ 1 +MMSE27	15 (47,0%)	42 (48,1%)	9 (42,6%)	$\chi^2= 9.918$	0.078
CDR ≥ 0.5	267 (47,0%)	218 (48,1%)	49 (42,6%)	$\chi^2= 1.120$	0.290
GDS	174 (30,6%)	137 (30,2%)	37 (32,2%)	$\chi^2= 0.161$	0.688
IADL	176 (31,0%)	137 (30,2%)	39 (33,9%)	$\chi^2= 0.578$	0.477
APOE Genotyping					
ApoE ε2 carriers	38 (7.5%)	35 (8.6%)	3 (3.0%)	$\chi^2=3.611$	0.057
ApoE ε3 carriers	494 (97.2%)	396 (97.1%)	98 (98.0%)	$\chi^2=0.265$	0.606
ApoE ε4 carriers	96(18.9%)	79 (19.4%)	17(17.0%)	$\chi^2=0.293$	0.589

A strong correlation between poor cognitive performance and diabetes was again observed (table 5) with a p-value of 0.072 for MMSE27 and p-value of 0.078 for CDR and MMSE positive individuals. Additionally it is also clear that the ApoE- $\epsilon$ 2 genotype (p-value of 0.057) is protective for diabetes, of note and as described in the introduction, it is also protective for AD.

The data here presented provides strong preliminary evidence linking poor cognitive scores to diabetes and validates the need to carry out further molecular and cell biology based studies.



## 4.2. Network analysis

#### 4.2.1. Key proteins interactomes

In order to understand the interrelationship of proteins we are increasingly resorting to mapping complex networks using a systems biology approach. Often the central point (protein/node) is a protein whose involvement has been well characterized for a given pathology; such as the APP in AD. Hence using the list of proteins in Table 1 and 2, see methods above, the interactome for each of the proteins involved in AD and IS was constructed. In essence a network was built for every key protein in both AD and IS pathway. An example is shown in Figure 5.




Figure 5 - APP interactome, as example.

To simplify the data output the number of interacting proteins with each of the search nodes/proteins is shown in Table 6 and 7. Of note, the IntAct database identifies the gene but given that we are discussing proteins the term protein will be used.

Table 6 - AD proteins and the number of interactors involved

	Gene name	Number of interactors
AD	APOE	25
	APP	84
	BACE1	5
	MAPT / TAU	28
	PSEN1	36
	PSEN2	21
	ADAM10	4
	ADAM17	8
	APH1A	14
	APH1B	1
	CAPN1	18
	CAPN2	11
	CASP3	40
	CASP7	12
	CDK5	58
	CDK5R1	7
	IDE	7
	LPL	14
	LRP1	17
	MME/NEP	81
	NCSTN	49
	PSENEN	7
	RTN3	20
	RTN4	38

Table 7- IS proteins and the number of interactors involved

	Gene name	Number of interactors
IS	AKT1	144
	AKT2	31
	AKT3	7
	GLUT4/SLC2A4	3
	GRB2	760
	GSK3A	28
	GSK3B	199
	INSR	35
	IRS1	23
	IRS2	15
	MAPK1	87
	MAPK3	88
	PIK3CA	38
	PIK3CB	13
	PIK3CD	9

	PIK3R1	186
	PIK3R2	50
	PIK3R3	123
	PDPK1	49
	SOS1	31
	SOS2	15
	HRAS	42
	KRAS	56
	NRAS	30
	ARAF	80
	RAF1	106
	BRAF	39
	MAP2K1	60
	MAP2K2	17
	MTOR	64
	BAD	34
	FOXO1	33

Consequently all the interacting networks for AD were merged, the same was carried out for the IS. Highly complex networks were obtained.

Obviously it is difficult to simultaneously address the functional significance of all the proteins/nodes present in the merged networks. Hence, a subsequent analysis was carried out to identify, which of the proteins present in the AD and IS pathways were also relevant to the synapse.

#### 4.2.2. *Synapse network correlation*

A synapse proteome network including 6900 proteins was created (data not shown) to correlate the presence of AD proteins in the synapse. This is singularly important as in AD synapses are destroyed, causing loss of communication between neurons and leading, in a final stage, to neuronal death. For this purpose, the 511 proteins retrieved from the merged network of key AD proteins, were crossed with the 6900 synapse proteins found in the literature. It was possible to identify that AD and the synapse are related, as 88% of the retrieved AD pathway proteins can be found in the synapse proteome (Supplementary table 1).

The same procedure was carried out for the IS pathway, in order to see the relevance of IS in the synapse. Although the number of IS proteins retrieved is much higher, 79% of these were present in the synapse which highlights the relevance of IS pathway to the synapse (Supplementary table 1).

If one considers the overlap between merged networks for the AD and IS pathways there are 156 shared nodes/proteins, these are discussed in more detail below, but of these 150 are also present in the synapse (Supplementary table 1). In other words 96% of AD and IS shared proteins can be found in the synapse, re-enforcing that the IS pathway in the synapse may be of critical importance to AD.

*Table 8- Number and percentage of proteins involved in each pathway and in the synapse.*

Pathway	Number of proteins retrieved from the disease	Number of proteins coincident with the synapse	Percentage of coincident proteins with the synapse
AD pathway	511	449	88%
IS pathway	1728	1358	79%
Coincident in AD and IS pathway	156	150	96%

#### *4.2.3. Alzheimer's disease and insulin signaling pathway correlation*

As mentioned above, 156 proteins/nodes were identified as coincident in AD and the IS pathways, but further analysis was required. The network of all AD retrieved proteins served as a template and all 156 proteins (Table 7) were marked to help visualize common proteins and their probable functions in AD (Figure 6 and 7).

Table 9- Proteins identified as coincident in AD and the IS pathway.

Gene names	Proteins full name
A2M	Alpha-2-macroglobulin
ABL1	Tyrosine-protein kinase ABL1
ACTB	Actin, cytoplasmic 1
ACTN1	Alpha-actinin-1
AKT1	RAC-alpha serine/threonine-protein kinase
AKT2	RAC-beta serine/threonine-protein kinase
AKT3	RAC-gamma serine/threonine-protein kinase
ALAS1	5-aminolevulinate synthase, nonspecific, mitochondrial
ANXA6	Annexin A6
APBB3	Amyloid-beta A4 precursor protein-binding family B member 3
APOA1	Apolipoprotein A-I
APOB	Apolipoprotein B-100
APP	Amyloid-beta A4 protein
AR	Androgen receptor
ARRB2	Beta-arrestin-2
ASCC2	Activating signal cointegrator 1 complex subunit 2
ATF2	Cyclic AMP-dependent transcription factor ATF-2
ATP5A1	ATP synthase subunit alpha, mitochondrial
BCAR3	Breast cancer anti-estrogen resistance protein 3
BCL2L1	Bcl-2-like protein 1
BIN1	Myc box-dependent-interacting protein 1
CALR	Calreticulin
CASP3	Caspase-3
CAST	Calpastatin
CCNB1	G2/mitotic-specific cyclin-B1
CCND1	G1/S-specific cyclin-D1
CCNI	Cyclin-I
CCT3	T-complex protein 1 subunit gamma
CCT7	T-complex protein 1 subunit eta
CCT8	T-complex protein 1 subunit theta
CDC37	Hsp90 co-chaperone Cdc37
CDC42	Cell division control protein 42 homolog
CDH1	Cadherin-1
CDKN1A	Cyclin-dependent kinase inhibitor 1
CDKN1B	Cyclin-dependent kinase inhibitor 1B
CEP126	Centrosomal protein of 126 kDa
CFL1	Cofilin-1
COPS6	COP9 signalosome complex subunit 6
CREB3	Cyclic AMP-responsive element-binding protein 3
CRELD2	Cysteine-rich with EGF-like domain protein 2
CTNNB1	Catenin beta-1
CTSD	Cathepsin D
CTTN	Src substrate cortactin
DBN1	Drebrin
DCTN1	Dynactin subunit 1
DIAPH1	Protein diaphanous homolog 1
DLG1	Disks large homolog 1

DLG4	Disks large homolog 4
DNAJB1	DnaJ homolog subfamily B member 2
DNM1	Dynamin-1
DYNC1H1	Cytoplasmic dynein 1 heavy chain 1
EEF1A1	Elongation factor 1-alpha 1
EGFR	Epidermal growth factor receptor
EPB41L3	Band 4.1-like protein 3
EZR	Ezrin
FHL2	Four and a half LIM domains protein 2
FIBP	Acidic fibroblast growth factor intracellular-binding protein
FLNA	Filamin-A
FLNB	Filamin-B
FTL	Ferritin light chain
FYN	Tyrosine-protein kinase Fyn
GAPDH	Glyceraldehyde-3-phosphate dehydrogenase
GCDH	Glutaryl-CoA dehydrogenase, mitochondrial
GFAP	Glial fibrillary acidic protein
GOLGA2	Golgin subfamily A member 2
GRB2	Growth factor receptor-bound protein 2
GSK3A	Glycogen synthase kinase-3 alpha
GSK3B	Glycogen synthase kinase-3 beta
HP	Heterochromatin protein 1
HSCB	Iron-sulfur cluster co-chaperone protein HscB, mitochondrial
HSP90AA1	Heat shock protein HSP 90-alpha
HSP90AB1	Heat shock protein HSP 90-beta
HSPA1A	Heat shock 70 kDa protein 1A
HSPA8	Heat shock cognate 71 kDa protein
HSPB1	Heat shock protein beta-1
IKBKE	Inhibitor of nuclear factor kappa-B kinase subunit epsilon
IMPDH2	Inosine-5'-monophosphate dehydrogenase 2
IRAK2	Interleukin-1 receptor-associated kinase-like 2
JAK3	Tyrosine-protein kinase JAK3
JUN	Transcription factor AP-1
KSR1	Kinase suppressor of Ras 1
LAMTOR1	Regulator complex protein LAMTOR1
LMNA	Prelamin-A/C
LRRK2	Leucine-rich repeat serine/threonine-protein kinase 2
LUC7L2	Putative RNA-binding protein Luc7-like 2
MAD2L1	Mitotic spindle assembly checkpoint protein MAD2A
MAP3K5	Mitogen-activated protein kinase kinase kinase 5
MAPT	Microtubule-associated protein tau
MDM2	E3 ubiquitin-protein ligase Mdm2
MED4	Mediator of RNA polymerase II transcription subunit 4
MEOX2	Homeobox protein MOX-2
MET	Hepatocyte growth factor receptor
MLH1	DNA mismatch repair protein Mlh1
MPP1	55 kDa erythrocyte membrane protein
MYH9	Myosin-9
NIF3L1	NIF3-like protein 1

NUMB	Protein numb homolog
PAK2	Serine/threonine-protein kinase PAK 2
PHB	Prohibitin
PIN1	Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1
PLEKHF2	Pleckstrin homology domain-containing family F member 2
PNKD	Probable hydrolase PNKD
PPIA	Peptidyl-prolyl cis-trans isomerase A
PPP1CA	Serine/threonine-protein phosphatase PP1-alpha catalytic subunit
PRKAB1	5'-AMP-activated protein kinase subunit beta-1
PSEN1	Presenilin-1
PTPN1	Tyrosine-protein phosphatase non-receptor type 1
PTPN3	Tyrosine-protein phosphatase non-receptor type 3
PTPN4	Tyrosine-protein phosphatase non-receptor type 4
PTPN5	Tyrosine-protein phosphatase non-receptor type 5
Q53FC7	Heat shock 70kDa protein 6 (HSP70B') variant
Q96BE0	Uncharacterized protein
RCAN1	Calcipressin-1
RET	Proto-oncogene tyrosine-protein kinase receptor Ret
RHEB	GTP-binding protein Rheb
RPL18A	60S ribosomal protein L18a
RPL30	60S ribosomal protein L30
RPP38	Ribonuclease P protein subunit p38
RPS23	40S ribosomal protein S23
RUVBL1	RuvB-like 1
RUVBL2	RuvB-like 2
SCAND1	SCAN domain-containing protein 1
SDF4	45 kDa calcium-binding protein
SHC1	SHC-transforming protein 1
SLC1A2	Excitatory amino acid transporter 2
SLC25A5	ADP/ATP translocase 2
SNCA	Alpha-synuclein
SORT1	Sortilin
SPG21	Maspardin
SPICE1	Spindle and centriole-associated protein 1
SPTAN1	Spectrin alpha chain, non-erythrocytic 1
SRC	Proto-oncogene tyrosine-protein kinase Src
SRI	Sorcin
STAT3	Signal transducer and activator of transcription 3
STIP1	Stress-induced-phosphoprotein 1
STK4	Serine/threonine-protein kinase 4
STUB1	E3 ubiquitin-protein ligase CHIP
TERF1	Telomeric repeat-binding factor 1
TFAP2A	Transcription factor AP-2-alpha
TGOLN2	Trans-Golgi network integral membrane protein 2
TIRAP	Toll/interleukin-1 receptor domain-containing adapter protein
TLE1	Transducin-like enhancer protein 1
TMED2	Transmembrane emp24 domain-containing protein 2
TNPO1	Transportin-1
TP53BP2	Apoptosis-stimulating of p53 protein 2

TTI1	TELO2-interacting protein 1 homolog
TUBB	Tubulin beta chain
UCHL1	Ubiquitin carboxyl-terminal hydrolase isozyme L1
UMPS	Uridine 5'-monophosphate synthase
VCAM1	Vascular cell adhesion protein 1
XIAP	E3 ubiquitin-protein ligase XIAP
YWHAE	14-3-3 protein epsilon
YWHAG	14-3-3 protein gamma
YWHAQ	14-3-3 protein theta
YWHAZ	14-3-3 protein zeta/delta
ZDHHC17	Palmitoyltransferase ZDHHC17

A summary of AD and IS coincident proteins is shown in Figure 6. In Figure 7 are represented all AD proteins retrieved in grey and the coincident proteins also present in the IS pathway are shown in green. Also, the size of the nodes vary according to the amount of control that this node exerts over the interactions of other nodes in the network. In other words, the node will grow according to the number of interactions it performs between communities. This method of analysis allows one to identify proteins with higher impact in different protein pathways.




Figure 6- Venn diagram of AD and IS proteins






Figure 7- All retrieved AD proteins. Grey nodes correspond to proteins only from AD while green nodes correspond to coincident proteins from AD and IS pathways. Bigger nodes correspond to proteins that are bridges between different communities, re-enforcing their importance by connecting diverse key proteins.

From the Figure 7, APP is clearly a central hub, and can be visualized as the protein with highest impact on AD. On a second plan, a few other proteins appear as central nodes, such as microtubule-associated protein tau (MAPT), presenilin-1 and 2 (PSEN1 and PSEN2), apolipoprotein E (ApoE), caspase-3 (CASP3), cyclin-dependent kinase 5 (CDK5) and Nicastrin (NCSTN).

Tau protein and ApoE also contribute to AD hallmarks, having great importance in the disease development as already discussed. PSEN-1, PSEN-2 and NCSTN are a part of the  $\gamma$ -secretase complex, responsible for APP cleavage. PSEN-1 and 2 mutations can cause autosomal dominant forms of early-onset AD<sup>68</sup>, meaning that although they are involved in both pathways of APP cleavage, they play a major role in A $\beta$  formation. Also CASP3 appears prominently and in association with the IS pathway. This protein is involved in the start of the cascade of caspases responsible for execution of apoptosis, leading to neuronal death. Insulin is capable of reducing CASP3 activity in retinal neurons, preventing apoptosis<sup>69</sup>. Impaired insulin signalling may play a pivotal role in the activation of apoptosis cascade. Finally, CDK5 also appears highlighted. A protein from the class of

proline-directed serine/threonine-protein kinases, involved in many important cellular processes such as neuronal cell cycle arrest and differentiation, apoptosis, regulation by phosphorylating key proteins in neuronal survival, axonal and neurite growth, synaptic plasticity and neurotransmission and is also able to phosphorylate Tau<sup>70</sup>.

In order to analyse all proteins together, a gene ontology (GO) study was conducted on proteins coincident in the AD and IS pathways. Biological processes and molecular functions were assessed to understand the molecular mechanisms behind AD and also the mechanisms of common proteins between AD and IS pathways. The GO analysis was performed using PANTHER. The output provides the number of proteins involved in the process from the 156 protein input list; a p-value calculated by binomial statistic is also presented (Tables 12 and 13). This p-value represents the probability that the number of genes observed in the category occurred by chance, in comparison with a reference database list. A small p-value indicates that the observed number is significant and potentially interesting.

Regarding the 511 proteins in the AD interactome network from this study, and with respect to biological processes (Table 8), the response to stimulus appeared with the highest number of hits, indicating that many of the proteins are key signal transducers. However, by considering the p-value, other processes appear to be more significant. With the lowest p-value being obtained for cellular component organization, which in AD is completely deregulated. From this analysis, more than 50% of the AD set of proteins appears to be involved in this process. In this set, all microtubule and microtubule associated proteins appear, namely microtubule-associated protein tau, one of the major proteins involved in AD. Furthermore, many nodes also appear to be associated with cell communication and signalling, with almost 50% of our dataset of proteins present in these categories and with relatively low p-values. This is suggestive of a high impact that this disease can have in cell signalling.

In the molecular functions (Table 9), with 90% of representation and an absurdly low p-value, we identified protein binding. Suggesting that this disease is not dependent on proteins alone but more protein complexes, which are more difficult to target than a single protein. It also reinforces that AD is a complex disease and many proteins can influence it. Of note, receptor binding was one of the top hits, with 20% of proteins from the set being able to bind to a receptor, probably leading to cascades of events. These cascades will lead to phosphorylation of other proteins, involving protein kinases and protein kinase binding, which was a molecular function associated with 14% of proteins (Table 9). This is a highly relevant molecular function, for instance playing an important role in tau hyperphosphorylation.

Table 10- Biological process analysis of interesting processes from AD proteins.

Biological process	Number of proteins	% from total	P value
Response to stimulus	339/511	66%	6.03E-12
Cellular component organization	282/511	55%	3.59E-40
Cell communication	244/511	48%	8.39E-21
Signalling	238/511	47%	1.74E-19

Table 11- Molecular function analysis of interesting functions from AD proteins.

Molecular function	Number of proteins	% from total	P value
Protein binding	461/511	90%	1.36E-57
Receptor binding	103/511	20%	9.34E-16
Kinase binding	73/511	14%	1.38E-22

For only the coincident proteins, the same analyses with the same parameters were performed. Interestingly, all biological processes and molecular functions (Table 10 and 11) have an increase in the percentage of representation. All the identified processes have an important impact on AD and the fact that all increased can mean that insulin signalling probably plays a pivotal role in many key proteins associated with AD.

Table 12- Biological process analysis of interesting processes from AD core proteins and only coincident proteins with IS pathway.

Biological process	Number of proteins	% from total	P value
Response to stimulus	120/156	77%	1.51E-18
Cellular component organization	104/156	67%	3.79E-23
Cell communication	90/156	58%	5.07E-13
Signalling	88/156	56%	2.44E-12


*Table 13- Molecular function analysis of interesting functions from AD core proteins and only coincident proteins with IS pathway.*

<b>Molecular function</b>	<b>Number of proteins</b>	<b>% from total</b>	<b>P value</b>
Protein binding	152/156	97%	5.26E-30
Receptor binding	46/156	30%	1.46E-12
Kinase binding	42/156	27%	1.71E-23

### 4.3. SH-SY5Y differentiation

Having established a strong correlation at a systems biology level, namely a strong overlap in the AD and IS networks it was deemed relevant to pursue correlations using a neuronal cell model.

The literature offers many methods to differentiate the SH-SY5Y cell line such as to achieve a neuronal like morphology. Upon consulting various protocols, the concentration of medium FBS and the exposure time of RA were the variants less defined. Thus, in this study, contrast-phase photographs were taken at day 0, day 3 and day 5 to visualize morphological differences in undifferentiated and differentiated cells in the presence of 1% and 10% FBS supplemented with 10  $\mu$ M of RA.



*Figure 8- Differentiation of SH-SY5Y cell line at different time points. The control is undifferentiated cells with complete growth medium. Both 1% FBS and 10% FBS were supplemented with 10  $\mu$ M of RA.*

Day 0 was the day after the seeding and no treatment had yet been performed, so all cells looked the same. At day 3, one can already distinguish 1% FBS and 10% FBS from the undifferentiated control. A more elongated phenotype and more neurites can be visualized in the 1% and 10% FBS concentrations, but no major differences between them. At day 5, the cells in 1% FBS appear to have formed much more neurites than the cells in 10% FBS or the control. The 5 day at 1% FBS protocol induced cells into a more mature neuron type and for this reason, this was the protocol used for the rest of the experiments.

## 4.4. Western blot analysis

Western blots were conducted using SH-SY5Y differentiated cells for 5 days with 10  $\mu$ M of RA and 1% FBS medium and treated with 0, 1, 10 and 100 nM of human insulin for 0, 10 and 60 minutes to assess the effect of insulin in AD related proteins. For this purpose, the levels of total tau, tau phosphorylated at serine 396, total APP and APP phosphorylated at threonine 668 were assessed.




Figure 9- Total Tau expression in SH-SY5Y differentiated cells treated with insulin. A- Western blot analysis of SH-SY5Y lysates treated with different concentrations and exposure times of insulin. B- Ponceau staining as loading control. C- Comparison of total Tau expression levels in different concentration and exposure times of insulin.

Regarding the levels of total Tau protein, a very small increase can be detected in the 10 minutes exposure to insulin, mainly in the 100nM (higher concentration), followed by a decrease after 60 minutes exposure. This decrease may be explained by cellular death due to toxic concentrations of insulin. It is possible to deduce that insulin does not appear to influence the expression of total Tau protein, at least during small exposure periods, as tested here.

For the phosphorylation of protein Tau, many residues appear phosphorylated in AD. The choice to study the serine 396 come from previous work from our laboratory pointing to a significant increase of phosphorylation at this residue in SH-SY5Y cells exposed to the A $\beta$  peptide<sup>23</sup> and its importance in the formation of paired helical Tau filaments (PHF).




Figure 10- Tau phosphorylation at serine 396 in SH-SY5Y differentiated cells treated with insulin. A- Western blot analysis of SH-SY5Y lysates treated with different concentrations and exposure times of insulin. B- Ponceau staining as loading control. C- Comparison of Tau phosphorylation at serine 396.

In relation to the phosphorylation of protein Tau at the serine 396, an increase can be detected independent of the concentrations of insulin and more dependent on the exposure time.

In order to better visualize the data referent to total Tau and Tau phosphorylated at serine 396, a ratio was performed (Figure 11).




Figure 11- Ratio between Tau phosphorylated at the serine 396 and total Tau.

From the ratio, it is possible to see that higher exposure times and higher concentrations of insulin can lead to an effect on Tau protein, but further studies are necessary to enable any conclusion.




Figure 12- Total APP expression in SH-SY5Y differentiated cells treated with insulin. A- Western blot analysis of SH-SY5Y lysates treated with different concentrations and exposure times of insulin. B- Ponceau staining as loading control. C- Comparison of total APP expression levels in different concentrations and exposure times of insulin.



Regarding APP, in the 10 minutes of exposure to insulin, an increase in the expression can be observed. However, while the SH-SY5Y cells were exposed to insulin for 60 minutes, a drastic decreased of total levels of APP in the higher concentrations can be noticed. A study performed in mice showed that the brain insulin receptor signalling mediated APP processing<sup>71</sup>, that is concurrent with the 60 minutes results reported. From the data here presented it seems reasonable to deduce that even short exposures to insulin appear to increase APP expression and possible APP processing. However to proof this further experimentation is necessary.

APP processing is intrinsically associated with its phosphorylation state. This applies to its intracellular trafficking as well as cleavage via different pathways and even A $\beta$  production<sup>72,73</sup>. Thus the phosphorylation at threonine 668 of APP was assessed. The phosphorylation of this specific residue was previously shown to be involved APP cleavage, promoting the amyloidogenic pathway<sup>10</sup>.




Figure 13- APP phosphorylation at threonine 668 in SH-SY5Y differentiated cells treated with insulin. A- Western blot analysis of SH-SY5Y lysates treated with different concentrations and exposure times of insulin. B- Ponceau staining as loading control. C- Comparison of APP phosphorylation at threonine 668 in different concentrations and exposure times of insulin.

It is possible to visualize a high increase in the phosphorylation of APP thr668 when exposed for 10 minutes to different concentration of insulin, followed by a decrease at 60 minutes of exposure. From these results it is possible to conclude that the insulin signalling may actually play a role in determining APP phosphorylation and be putatively involved in A $\beta$  production. The decrease in the phosphorylation of this residue at 60 minutes of insulin exposure may be related to a decrease in total APP. This question deserves to be further investigated.

Regarding the literature, almost all research conducted in insulin and AD report an anti-amyloidogenic effect of insulin, due to a decrease in phosphorylation of APP at threonine 668, inactivation of GSK3 $\beta$  and decrease of  $\beta$ -secretase activity<sup>74</sup>. A study conducted in SH-SY5Y cells relate the decreasing phosphorylation of APP thr668 with the same concentrations of insulin used in this study, but for a higher exposure time (24h)<sup>74</sup> and this appeared to be beneficial to AD. Another study made the same assumptions based in reduced APP Thr668 phosphorylation in long term administration in young adult mice with AD phenotype with intranasal administration of insulin<sup>75</sup>. While the data here presented also reveals a decreased phosphorylation at 60 minutes the shorter exposure period is contradictory. Namely shorter exposure periods appear to result in increased phosphorylation of APP-Thr668.

Insulin may actually play an important role as an anti-amyloidogenic but the results obtained in this study show that it may not be as linear as initially thought. The level of APP phosphorylation on Thr668 appears to be concentration and time of exposure dependent. Clearly the issue has to be further investigated.

## 4.5. Resazurin assay analysis

A resazurin assay was performed to assess cell viability to confirm that the obtained results were real and not due to insulin toxicity and cellular death.




Figure 14 -Resazurin assay. Viability of SH-SY5Y differentiated cells pre-treated with 0, 1, 10 and 100 nM of insulin for 0, 10 and 60 minutes.

As it can be seen in the Figure 13, no differences can be observed from cell viability, discarding the hypothesis that insulin could toxically interfere with the results. On the other hand, insulin can still be toxic at higher exposure times, as it can lead to A $\beta$  production. This however, was not tested.



## **5. Conclusion**



## 5. Conclusion

Growing evidence links impaired brain insulin signalling and insulin resistance to the development of AD. A correlation between diabetes and poor cognitive scores in MMSE tests were observed, linking diabetes to a deteriorating cognition. Additionally, carriers of the allele ApoE- $\epsilon$ 2 showed to be protected against diabetes, as seen for AD.

Nonetheless, the majority of proteins in AD and in IS pathways, were shown to be present in the synapse, re-enforcing their roles in synaptic signalling and plasticity. Coincident proteins on AD and IS pathways had 96% of representation in the synapse proteome, strengthening their role in the synapse as well as the relevance of IS to AD.

A gene ontology study was also conducted, in order to assess the most important biological processes and molecular function of the proteins involved. As for AD, response to stimulus, cellular component organization, cell communication, signalling, protein binding, receptor binding and kinase binding were categories with elevated representation. Regarding coincident proteins between AD and IS pathways, an increase in all categories was observed, suggesting that insulin plays a pivotal role in many AD related events.

Finally, the analysis of western blots performed in differentiated SH-SY5Y cells treated with different concentrations and exposure times of insulin displayed interesting preliminary results. For Tau protein, a decrease in the intracellular levels of total Tau and an increase in the phosphorylation of serine 396 was observed, with clear evidence when a ration between Tau phosphorylated and total Tau is performed. On the other hand, regarding APP, an increase in the expression at 10 minutes of exposure followed by a decrease at 60 minutes of insulin exposure was observed. This can mean that insulin plays a role in the expression/processing of APP. As for the phosphorylation of threonine 668 of APP, which, in the literature, has been shown to favour A $\beta$  production by promoting the cleavage by amyloidogenic pathway, was increased in the cells treated with insulin at 10 minutes, leading one to propose that short exposure to insulin may actually promote A $\beta$  production.

Insulin signalling plays an unquestionable role in memory and cognition, and consequently in AD, but further work is necessary to understand all the mechanisms behind these cascades of events.





## **6. References**



## 6. References

1. Martin Prince, A. *et al.* World Alzheimer Report 2015 The Global Impact of Dementia Analysis of prevalence, incidence, cost and trends. (2015).
2. Querfurth, H. W. & LaFerla, F. M. Alzheimer's Disease. *N. Engl. J. Med.* **362**, 329–344 (2010).
3. Szekely, C. A. *et al.* Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. *Neuroepidemiology* **23**, 159–69 (2004).
4. Waxman, S. G. *From neuroscience to neurology : neuroscience, molecular medicine, and the therapeutic transformation of neurology.* (Elsevier Academic Press, 2005).
5. Martins, I. J. *et al.* Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. *Mol. Psychiatry* **11**, 721–736 (2006).
6. Salawu, F., Umar, J. & Olokoba, A. Alzheimer's disease: A review of recent developments. *Ann. Afr. Med.* **10**, 73 (2011).
7. Schmand, B., Smit, J. H., Geerlings, M. I. & Lindeboom, J. The effects of intelligence and education on the development of dementia. A test of the brain reserve hypothesis. *Psychol. Med.* **27**, 1337–44 (1997).
8. Fleminger, S., Oliver, D. L., Lovestone, S., Rabe-Hesketh, S. & Giora, A. Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. *J. Neurol. Neurosurg. Psychiatry* **74**, 857–62 (2003).
9. Mittal, K., Mani, R. J. & Katare, D. P. Type 3 Diabetes: Cross Talk between Differentially Regulated Proteins of Type 2 Diabetes Mellitus and Alzheimer's Disease. *Sci. Rep.* **6**, 25589 (2016).
10. Lee, M.-S. *et al.* APP processing is regulated by cytoplasmic phosphorylation. *J. Cell Biol.* **163**, 83–95 (2003).
11. Kamenetz, F. *et al.* APP Processing and Synaptic Function. *Neuron* **37**, 925–937 (2003).
12. Wang, J.-Z., Xia, Y.-Y., Grundke-Iqbal, I. & Iqbal, K. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. *J. Alzheimers. Dis.* **33 Suppl 1**, S123-39 (2013).
13. Oliveira, J., Costa, M., De Almeida, M. S. C., Da Cruz E Silva, O. A. B. & Henriques, A. G. Protein Phosphorylation is a Key Mechanism in Alzheimer's Disease. *J. Alzheimer's Dis.* **58**, 953–978 (2017).
14. Huang, W.-J., Zhang, X. & Chen, W.-W. Role of oxidative stress in Alzheimer's disease. *Biomed. reports* **4**, 519–522 (2016).
15. Ring, S. *et al.* The Secreted  $\beta$ -Amyloid Precursor Protein Ectodomain APPs Is Sufficient to Rescue the Anatomical, Behavioral, and Electrophysiological Abnormalities of APP-Deficient Mice. *J. Neurosci.* **27**, 7817–7826 (2007).

16. O'Brien, R. J. & Wong, P. C. Amyloid precursor protein processing and Alzheimer's disease. *Annu. Rev. Neurosci.* **34**, 185–204 (2011).
17. Kojro, E. & Fahrenholz, F. The non-amyloidogenic pathway: structure and function of alpha-secretases. *Subcell. Biochem.* **38**, 105–27 (2005).
18. Thinakaran, G. & Koo, E. H. Amyloid Precursor Protein Trafficking, Processing, and Function. *J. Biol. Chem.* **283**, 29615–29619 (2008).
19. Pająk, B., Kania, E. & Orzechowski, A. Killing Me Softly: Connotations to Unfolded Protein Response and Oxidative Stress in Alzheimer's Disease. *Oxid. Med. Cell. Longev.* 1–17 (2016).
20. Wischik, C. M., Crowther, R. A., Stewart, M. & Roth, M. Subunit structure of paired helical filaments in Alzheimer's disease. *J. Cell Biol.* **100**, 1905–12 (1985).
21. Qiang, L., Yu, W., Andreadis, A., Luo, M. & Baas, P. W. Tau Protects Microtubules in the Axon from Severing by Katanin. *J. Neurosci.* **26**, 3120–3129 (2006).
22. Šimić, G. *et al.* Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies. *Biomolecules* **6** (2016).
23. Oliveira, J. M., Henriques, A. G., Martins, F., Rebelo, S. & Da Cruz E Silva, O. A. B. Amyloid- $\beta$  Modulates Both A $\beta$ PP and Tau Phosphorylation. *J. Alzheimer's Dis.* **45**, 495–507 (2015).
24. Boucher, J., Kleinridders, A. & Kahn, C. R. Insulin receptor signaling in normal and insulin-resistant states. *Cold Spring Harb. Perspect. Biol.* **6**, (2014).
25. Chang, L., Chiang, S.-H. & Saltiel, A. R. Insulin signaling and the regulation of glucose transport. *Mol. Med.* **10**, 65–71 (2004).
26. Van Obberghen, E. *et al.* Surfing the insulin signaling web. *Eur. J. Clin. Invest.* **31**, 966–977 (2001).
27. Lizcano, J. M. & Alessi, D. R. The insulin signalling pathway. *Curr. Biol.* **12**, R236-8 (2002).
28. Dong Chen, D., Waters, S. B., Holt, K. H. & Pessin, J. E. SOS phosphorylation and disassociation of the Grb2-SOS complex by the ERK and JNK signaling pathways. *J. Biol. Chem.* **271**, 6328–32 (1996).
29. Gray, S. M., Meijer, R. I. & Barrett, E. J. Insulin regulates brain function, but how does it get there? *Diabetes* **63**, 3992–7 (2014).
30. Blázquez, E., Velázquez, E., Hurtado-Carneiro, V. & Ruiz-Albusac, J. M. Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer's disease. *Front. Endocrinol.* **5**, 161 (2014).
31. Plum, L., Schubert, M. & Brüning, J. C. The role of insulin receptor signaling in the brain. *Trends Endocrinol. Metab.* **16**, 59–65 (2005).
32. Hui, H., Tang, G. & Go, V. Hypoglycemic herbs and their action mechanisms. *Chin. Med.* **4**, 11 (2009).
33. Kashyap, S. *et al.* A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. *Diabetes* **52**, 2461–74 (2003).

34. Kahn, S. E., Hull, R. L. & Utzschneider, K. M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature* **444**, 840–846 (2006).
35. Group, D. P. P. R. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. *N. Engl. J. Med.* **346**, 393–403 (2002).
36. Gutiérrez-Rodelo, C., Roura-Guiberna, A. & Olivares-Reyes, J. A. Molecular Mechanisms of Insulin Resistance: An Update.
37. Hoyer, S. Der Aminosäuren-Stoffwechsel des normalen menschlichen Gehirns. *Klin. Wochenschr.* **48**, 1239–1243 (1970).
38. Talbot, K. *et al.* Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. *J. Clin. Invest.* **122**, 1316–38 (2012).
39. Duelli, R., Schröck, H., Kuschinsky, W. & Hoyer, S. Intracerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats. *Int. J. Dev. Neurosci.* **12**, 737–43 (1994).
40. Wang, X. *et al.* Insulin inhibits A $\beta$  production through modulation of APP processing in a cellular model of Alzheimer's disease. *Neuroendocr. Lett Neuroendocrinol. Lett.* **35**, 224–229 (2014).
41. Welsh, G. I. & Proud, C. G. Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. *Biochem. J.* **294 ( Pt 3)**, 625–9 (1993).
42. Troussard, A. A., Tan, C., Yoganathan, T. N. & Dedhar, S. Cell-extracellular matrix interactions stimulate the AP-1 transcription factor in an integrin-linked kinase- and glycogen synthase kinase 3-dependent manner. *Mol. Cell. Biol.* **19**, 7420–7 (1999).
43. Turenne, G. A. & Price, B. D. Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53's transcriptional activity. *BMC Cell Biol.* **2**, 12 (2001).
44. Anderton, B. H. *et al.* Sites of phosphorylation in tau and factors affecting their regulation. *Biochem. Soc. Symp.* 73–80 (2001).
45. Brion, J. P. *et al.* Neurofibrillary tangles and tau phosphorylation. *Biochem. Soc. Symp.* 81–8 (2001).
46. Hernández, F., Langa, E., Cuadros, R., Avila, J. & Villanueva, N. Regulation of GSK3 isoforms by phosphatases PP1 and PP2A. *Mol. Cell. Biochem.* **344**, 211–215 (2010).
47. Vintém, A. P. B., Henriques, A. G., da Cruz e Silva, O. A. B. & da Cruz e Silva, E. F. PP1 inhibition by A $\beta$  peptide as a potential pathological mechanism in Alzheimer's disease. *Neurotoxicol. Teratol.* **31**, 85–88 (2009).
48. Yu, J.-T., Tan, L. & Hardy, J. Apolipoprotein E in Alzheimer's Disease: An Update. *Annu. Rev. Neurosci.* **37**, 79–100 (2014).
49. Mahley, R. W., Weisgraber, K. H. & Huang, Y. Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease. *Proc. Natl. Acad. Sci.* **103**, 5644–5651 (2006).
50. Filippi, B. M., Mighiu, P. I. & Lam, T. K. T. Is Insulin Action in the Brain Clinically Relevant?

*Diabetes* **61**, 773–775 (2012).

51. Reger, M. A. *et al.* Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype. *Neurobiol. Aging* **27**, 451–458 (2006).
52. Reger, M. A. *et al.* Intranasal insulin improves cognition and modulates  $\beta$ -amyloid in early AD. *Neurology* **70**, 440–448 (2008).
53. Craft, S. *et al.* Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. *Psychoneuroendocrinology* **28**, 809–22 (2003).
54. Chan, E. S., Chen, C., Cole, G. M. & Wong, B.-S. Differential interaction of Apolipoprotein-E isoforms with insulin receptors modulates brain insulin signaling in mutant human amyloid precursor protein transgenic mice. *Sci. Rep.* **5**, 13842 (2015).
55. Qiu, W. Q. *et al.* Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. *J. Biol. Chem.* **273**, 32730–8 (1998).
56. Vekrellis, K. *et al.* Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. *J. Neurosci.* **20**, 1657–65 (2000).
57. Lee, Y. H. & White, M. F. Insulin receptor substrate proteins and diabetes. *Arch. Pharm. Res.* **27**, 361–70 (2004).
58. Zhang, M., Lv, X.-Y., Li, J., Xu, Z.-G. & Chen, L. The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. *Exp. Diabetes Res.* **2008**, 704045 (2008).
59. Gupta, A., Bisht, B. & Dey, C. S. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. *Neuropharmacology* **60**, 910–920 (2011).
60. Rosa, I. M., Henriques, A. G., Carvalho, L., Oliveira, J. & da Cruz e Silva, O. A. B. Screening Younger Individuals in a Primary Care Setting Flags Putative Dementia Cases and Correlates Gastrointestinal Diseases with Poor Cognitive Performance. *Dementia and Geriatric Cognitive Disorders*. **43**, 15–28 (2017).
61. Morris, J. C. The Clinical Dementia Rating (CDR): current version and scoring rules. *Neurology* **43**, 2412–4 (1993).
62. Yesavage, J. A. & Sheikh, J. I. 9/Geriatric Depression Scale (GDS). *Clin. Gerontol.* **5**, 165–173 (1986).
63. Katz, S. Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living. *J. Am. Geriatr. Soc.* **31**, 721–7 (1983).
64. Lawton, M. P. & Brody, E. M. Assessment of older people: self-maintaining and instrumental activities of daily living. *Gerontologist* **9**, 179–86 (1969).
65. Morgado, J., Rocha, C., Maruta, C., Guerreiro, M. & Martins, I. Morgado: Novos valores normativos do mini-mental.
66. Morgado, J., Rocha, C. S., Maruta, C., Guerreiro, M. & Martins, I. P. Cut-off scores in MMSE: a moving target? *Eur. J. Neurol.* **17**, 692–695 (2010).

67. Rosa, I., Henriques, A. & Da Cruz e Silva, O. Cognitive Performance of Primary Care based Cohort using Mini Mental State Examination.
68. Lanoiselée, H.-M. *et al.* APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. *PLoS Med.* **14**, e1002270 (2017).
69. Barber, A. J. *et al.* Insulin rescues retinal neurons from apoptosis by a phosphatidylinositol 3-kinase/Akt-mediated mechanism that reduces the activation of caspase-3. *J. Biol. Chem.* **276**, 32814–21 (2001).
70. Kimura, T., Ishiguro, K. & Hisanaga, S.-I. Physiological and pathological phosphorylation of tau by Cdk5. *Front. Mol. Neurosci.* **7**, 65 (2014).
71. Stöhr, O. *et al.* Insulin receptor signaling mediates APP processing and  $\beta$ -amyloid accumulation without altering survival in a transgenic mouse model of Alzheimer's disease. *Age (Dordr.)* **35**, 83–101 (2013).
72. Gandy, S. *et al.* Amyloid Precursor Protein Sorting and Processing: Transmitters, Hormones, and Protein Phosphorylation Mechanisms. *Intracellular Traffic and Neurodegenerative Disorders* 1–9.
73. Henriques, A. G. *et al.* Altered protein phosphorylation as a resource for potential AD biomarkers. *Sci. Rep.* **6**, 30319 (2016).
74. Pandini, G. *et al.* Insulin Has Multiple Anti-amyloidogenic Effects on Human Neuronal Cells. *Endocrinology* **154**, 375–387 (2013).
75. Mao, Y.-F. *et al.* Intranasal insulin alleviates cognitive deficits and amyloid pathology in young adult APP<sup>swe</sup>/PS1<sup>dE9</sup> mice. *Aging Cell* **15**, 893–902 (2016).





## **7.Appendix**



## 7. Appendix

### Cell Culture Solutions

#### ▪ **PBS (1x)**

For a final volume of 500 mL, dissolve one pack of BupH Modified Dulbecco's Phosphate Buffered Saline Pack (Pierce) in deionized H<sub>2</sub>O. Final composition:

- 8 mM Sodium Phosphate
- 2 mM Potassium Phosphate
- 140 mM Sodium Chloride
- 10 mM Potassium Chloride

Sterilize by filtering through a 0.2 µm filter and store at 4°C.

#### ▪ **10% FBS MEM:F12 (1:1)**

- 4.805 g MEM
- 5.315 g F12
- 1.5 g NaHCO<sub>3</sub>
- 0.055 g Sodium Pyruvate
- 10 mL Streptomycin/Penicillin/Amphotericin solution
- 100 mL 10% FBS
- 2.5 mL L-glutamine (200 mM stock solution)

Dissolve in deionized H<sub>2</sub>O. Adjust the pH to 7.2-7.3. Adjust the volume to 1000 mL with deionized H<sub>2</sub>O.

For other combinations of FBS, replace 100 mL FBS with 30 mL (3% FBS MEM:F12), 10 mL (1% FBS MEM:F12) or remove FBS (serum-free MEM:F12).

### Western Blot Solutions

#### ▪ **LGB (lower gel buffer) (4x)**

To 900 mL of deionized H<sub>2</sub>O add:

- 181.65 g of Tris
- 4 g of SDS

Mix until the solutes have dissolved. Adjust pH to 8.9 and adjust the volume to 1 L with deionized H<sub>2</sub>O.

#### ▪ **UGB (Upper gel buffer) (4x)**

To 900 mL of deionized H<sub>2</sub>O add:

- 75.69 g of Tris

Mix until the solute has dissolved. Adjust the pH to 6.8 and adjust the volume to 1 L with deionized H<sub>2</sub>O.

- **10% APS (ammonium persulfate)**

In 10 mL of deionized H<sub>2</sub>O dissolve 1 g of APS. Note: prepare fresh before use.

- **10% SDS (sodium dodecylsulfate)**

In 10 mL of deionized H<sub>2</sub>O dissolve 1 g of SDS.

- **Loading Gel Buffer (4x)**

- 2.5 mL 1M Tris solution (pH 6.8) 2.5 mL (250 mM)
- 0.8 g SDS (8%)
- 4 mL Glycerol (40%)
- 2 mL β-mercaptoethanol (2%)
- 1 mg Bromofenol blue (0.01%)

Adjust the volume to 10 mL with deionized H<sub>2</sub>O. Store in darkness at room temperature.

- **1 M Tris (pH 6.8) solution**

To 150 mL of deionized H<sub>2</sub>O add:

- 30.3 g Tris base

Adjust the pH to 6.8 and adjust the final volume to 250 mL with deionized H<sub>2</sub>O.

- **10x Running Buffer**

- 30.3 g Tris (250 mM)
- 144.2 g Glycine (2.5 M)
- 10 g SDS (1%)

Dissolve in deionized H<sub>2</sub>O, adjust the pH to 8.3 and adjust the volume to 1 L.

Supplementary table 1- All synapse proteins

A0A024R5S0	ACHE	ADGRA2	AIFM3	AMFR	ANXA2	APPL1	ARHGEF1
A0A1B0G2W0	ACIN1	ADGRA3	AIG1	AMIGO2	ANXA6	APTX	9
A1BG	ACLY	ADGRB2	AIM1	AMMECR1	ANXA7	AQP1	ARHGEF2
A1DRY3	ACOT7	ADGRB3	AIM2	1	AOAH	AQP3	ARHGEF3
A2M	ACP1	ADGRL1	AIMP2	AMOT	AOC3	AR	ARHGEF4
A4GALT	ACP6	ADGRL2	AIP	AMOTL1	AOPEP	ARAP2	ARHGEF5
A6NNT2	ACSBG1	ADH6	AIPL1	AMOTL2	AP1B1	ARAP3	ARHGEF6
A8K1F4	ACSL3	ADIRF	AIRE	AMPD3	AP1G1	ARC	ARHGEF7
A8KAD6	ACSL4	ADNP	AJAP1	AMPH	AP1G2	ARF1	ARID3A
AAK1	ACSL5	ADO	AK2	AMZ2	AP1M1	ARF4	ARID4B
AAMDC	ACTA1	ADORA1	AK3	ANAPC10	AP1M2	ARF5	ARID5A
AARD	ACTA2	ADORA2	AK5	ANAPC15	AP1S1	ARF6	ARID5B
AARSD1	ACTB	A	AK8	ANAPC4	AP1S2	ARFGAP1	ARIH2
AASS	ACTBL2	ADRA1B	AKAP1	ANAPC5	AP1S3	ARFGAP3	ARKL1
AATK	ACTC1	ADRA1D	AKAP10	ANAPC7	AP2A1	ARFGEF1	ARL1
ABCA1	ACTG1	ADRA2B	AKAP11	ANG	AP2A2	ARFGEF2	ARL15
ABCA2	ACTG2	ADRA2C	AKAP12	ANGEL2	AP2B1	ARFGEF3	ARL16
ABCA3	ACTL6B	ADRB1	AKAP14	ANGPT1	AP2M1	ARFIP1	ARL2BP
ABCB7	ACTL7A	ADRB2	AKAP17A	ANGPTL4	AP2S1	ARFIP2	ARL3
ABCC1	ACTN1	ADRB3	AKAP2	ANGPTL7	AP3B1	ARHGAP1	ARL4D
ABCC2	ACTN2	ADRM1	AKAP5	ANK1	AP3B2	ARHGAP1	ARL6IP1
ABCC4	ACTN3	AEBP2	AKAP6	ANK2	AP3D1	0	ARL8B
ABCD1	ACTN4	AEN	AKAP7	ANK3	AP3M1	ARHGAP1	ARMC1
ABCD3	ACTR1B	AES	AKAP8	ANKFY1	AP3S1	1A	ARMC10
ABCE1	ACTR2	AFAP1	AKAP8L	ANKHD1	APAF1	ARHGAP1	ARMC6
ABCF2	ACTR3	AFARP1	AKAP9	ANKRA2	APBA1	5	ARMC8
ABCF3	ACTR3B	AFDN	AKIRIN1	ANKRD11	APBA2	ARHGAP1	ARMCX1
ABCG2	ACTR6	AFG3L2	AKT1	ANKRD17	APBA3	7	ARMCX3
ABCG4	ACTRT1	AGAP1	AKT2	ANKRD24	APBB1	ARHGAP2	ARNT2
ABCG5	ACVR1	AGBL5	AKTIP	ANKRD27	APBB1IP	1	ARNTL
ABHD11	ACVR2A	AGER	ALAS1	ANKRD28	APBB2	ARHGAP2	ARNTL2
ABHD15	ACVRL1	AGFG1	ALB	ANKRD34	APBB3	2	ARPC1A
ABHD5	ADAM10	AGGF1	ALCAM	A	APC	ARHGAP2	ARPC1B
ABI1	ADAM15	AGO1	ALDH18A	ANKRD36	APCS	4	ARPC2
ABI2	ADAM17	AGO2	1	BP1	APEX1	ARHGAP2	ARPC3
ABI3	ADAM20	AGO3	ALDH3A2	ANKRD46	APH1A	6	ARPC4
ABI3BP	ADAM22	AGO4	ALDH6A1	ANKRD50	APIP	ARHGAP3	ARPC5
ABL1	ADAM9	AGPS	ALDH7A1	ANKRD55	APLP1	1	ARPC5L
ABL2	ADAMTS	AGR3	ALDH8A1	ANKS1A	APLP2	ARHGAP3	ARR3
ABLM1	12	AGRN	ALDOA	ANKS1B	APOA1	2	ARRB1
ABLM3	ADAMTSL	AGTPBP1	ALDOB	ANKS4B	APOA4	ARHGAP3	ARRB2
ABR	4	AGTR1	ALG8	ANKS6	APOB	3	ARRDC3
ABT1	ADAP1	AGTRAP	ALKBH3	ANLN	APOBEC3	ARHGAP3	ARVCF
ACACA	ADAP2	AGXT	ALKBH8	ANO3	B	9	ARX
ACAD8	ADAR	AHCTF1	ALOX5	ANO5	APOBEC3	ARHGAP4	ASAP1
ACAD9	ADARB2	AHDC1	ALPP	ANO9	G	4	ASAP2
ACADVL	ADCK5	AHI1	ALS2	ANOS1	APOC3	ARHGDIA	ASB10
ACAP1	ADCY3	AHNAK	ALS2CR1	ANP32A	APOE	ARHGDIB	ASB13
ACAT2	ADCYAP1	AHNAK2	1	ANP32B	APOH	ARHGEF1	ASB16
ACBD5	ADCYAP1	AHSA1	ALS2CR1	ANTXR1	APOL2	1	ASCC1
ACD	R1	AHSG	2	ANTXR2	APOL3	ARHGEF1	ASCC2
ACE2	ADD1	AICDA	ALYREF	ANXA1	APOL5	2	ASF1A
	ADD3	AIDA	AMBRA1	ANXA10	APP	ARHGEF1	ASGR2
	ADGRA1	AIFM1	AMER1	ANXA11	APPBP2	7	ASH2L

ASIC1	ATP6V0A	BAG4	BEST4	BRD7	C1QTNF6	CACNA2D	CASC3
ASIC2	1	BAG5	BET1	BRE	C1QTNF8	1	CASK
ASIC4	ATP6V0C	BAG6	BEX1	BRF1	C1QTNF9	CACNB3	CASKIN1
ASNA1	ATP6V0D	BAHCC1	BEX2	BRINP1	C1QTNF9	CACNB4	CASP1
ASNS	1	BAHD1	BFSP2	BRIX1	B-AS1	CACNG2	CASP10
ASPH	ATP6V1A	BAI1	BHLHB9	BRK1	C1S	CACYBP	CASP2
ASRGL1	ATP6V1B	BAIAP2	BHLHE40	BRMS1	C1orf105	CAD	CASP3
ASTE1	1	BAIAP2L1	BICD1	BRMS1L	C1orf109	CADM1	CASP4
ASXL1	ATP6V1B	BAIAP3	BID	BRPF3	C1orf116	CADPS	CASP6
ATAD1	2	BAK1	BIK	BRSK1	C1orf216	CADPS2	CASP8
ATAD2B	ATP6V1E	BAMBI	BIN1	BSCL2	C1orf52	CALB1	CASP8AP
ATAD3A	1	BANP	BIN3	BSG	C1orf94	CALCA	2
ATCAY	ATP6V1G	BAP1	BIRC2	BSN	C20orf14	CALCOCO	CASP9
ATF2	1	BARD1	BIRC3	BTBD10	1	1	CAST
ATF4	ATP6V1H	BASP1	BIRC6	BTBD2	C20orf27	CALCOCO	CAT
ATF5	ATP7A	BATF	BLK	BTBD3	C22orf39	2	CATSPER
ATF6	ATPAF2	BATF3	BLMH	BTF3	C2CD5	CALCR	1
ATF7	ATPIF1	BAX	BLNK	BTG3	C2orf73	CALD1	CAV1
ATF7IP	ATR	BAZ1A	BLOC1S1	BTB	C2orf82	CALM1	CAV2
ATG10	ATRNB	BAZ2A	BLOC1S2	BTN2A2	C2orf88	CALML3	CAV3
ATG12	ATRX	BAZ2B	BLOC1S3	BTN2A3P	C3orf67	CALML5	CBARP
ATG3	ATXN1	BBC3	BLOC1S4	BTRC	C4A	CALR	CBFA2T3
ATG4A	ATXN10	BBS1	BLOC1S5	BUB1	C4B	CALU	CBFB
ATG4C	ATXN2	BBS10	BLOC1S6	BUB1B	C4BPA	CALY	CBL
ATG5	ATXN3	BBS2	BLVRB	BUD31	C4orf17	CAMK1D	CBLB
ATG7	ATXN7	BBS4	BLZF1	BYSL	C4orf3	CAMK2A	CBLC
ATG9A	ATXN7L3	BBS5	BMF	BZW2	C4orf42	CAMK2B	CBLL1
ATIC	AUP1	BBX	BMI1	C10orf35	C4orf46	CAMK2D	CBLN4
ATL2	AURKA	BCAP31	BMP2K	C11orf57	C6	CAMK2G	CBR1
ATL3	AURKB	BCAR1	BMP8A	C11orf65	C6orf120	CAMKK2	CBS
ATM	AURKC	BCAR3	BMP8B	C11orf84	C6orf141	CAMLG	CBWD1
ATN1	AVPI1	BCAS3	BMPR1B	C12orf10	C6orf203	CAMSAP	CBWD3
ATP12A	AXIN1	BCCIP	BMPR2	C14orf1	C6orf222	2	CBWD5
ATP13A2	AXIN2	BCKDHA	BMX	C14orf15	C7orf25	CAMSAP	CBX1
ATP1A1	AXL	BCKDK	BNIP1	9	C7orf43	3	CBX3
ATP1A2	B2M	BCL10	BNIP2	C14orf16	C7orf50	CAMTA2	CBX4
ATP1A3	B2R4U6	BCL11A	BNIP3	6	C8orf30A	CANX	CBX6
ATP1B1	B2R550	BCL2	BNIP3L	C15orf39	C8orf33	CAP2	CBX8
ATP2A2	B3GAT1	BCL2L1	BNIP1L	C15orf57	C8orf59	CAPN1	CBY1
ATP2B1	B4DMS2	BCL2L11	BOLA2	C15orf59	C9JAW5	CAPN10	CC2D1A
ATP2B2	B4DN30	BCL2L13	BOLA3	C16orf74	C9orf106	CAPN11	CC2D2A
ATP2B4	B4DRL9	BCL2L14	BOP	C17orf50	C9orf163	CAPN2	CCAR2
ATP4B	B4DYC6	BCL3	BOP1	C17orf53	C9orf72	CAPN3	CCBE1
ATP5A1	B4E2V5	BCL6	BORCS6	C17orf62	C9orf75	CAPN7	CCDC102
ATP5B	B4GALT1	BCL7B	BORCS8	C17orf67	C9orf78	CAPNS1	A
ATP5C1	B7Z2Y1	BCL9	BPGAP1	C17orf82	CAAP1	CAPRN1	CCDC102
ATP5D	B9D1	BCL9L	BPGM	C19orf25	CABLES1	CAPRN2	B
ATP5F1	B9D2	BCLAF1	BPIFA1	C19orf47	CABLES2	CAPZA1	CCDC103
ATP5G1	BAAT	BCOR	BPY2C	C19orf57	CABP1	CAPZA2	CCDC113
ATP5H	BABAM1	BCR	BRAF	C19orf60	CABP5	CAPZB	CCDC115
ATP5I	BACE1	BCR/ABL	BRAP	C1QA	CABYR	CARD10	CCDC120
ATP5J2	BACH2	fusion	BRCA1	C1QBP	CACHD1	CARD11	CCDC125
ATP5L	BAD	BDP1	BRCA2	C1QL1	CACNA1A	CARD9	CCDC13
ATP5O	BAG1	BECN1	BRD1	C1QTNF1	CACNA1B	CARHSP1	CCDC136
ATP6AP1	BAG2	BEGAIN	BRD2	C1QTNF2	CACNA1C	CARM1	CCDC14
ATP6AP2	BAG3	BEND3	BRD4	C1QTNF3	CACNA1F	CASC1	CCDC141

CCDC146	CCNO	CDC42EP	CDKN2B	CEP97	CHRM2	CLOCK	COG5
CCDC149	CCNY	2	CDKN2C	CEPT1	CHRM3	CLPP	COG6
CCDC153	CCNYL1	CDC42EP	CDKN2D	CERS2	CHRM4	CLPTM1L	COG7
CCDC155	CCP110	3	CDR2	CETN1	CHRM5	CLRN3	COIL
CCDC158	CCR10	CDC42EP	CDR2L	CETN2	CHRNA1	CLSTN1	COL17A1
CCDC18	CCR5	4	CDRT15	CETP	CHRNA3	CLSTN3	COL18A1
CCDC180	CCSER1	CDC42SE	CDSN	CFAP20	CHRNA4	CLTA	COL1A2
CCDC181	CCSER2	1	CDT1	CFAP206	CHRNA5	CLTB	COL27A1
CCDC184	CCT2	CDC42SE	CEACAM	CFAP36	CHRNA6	CLTC	COL4A3B
CCDC185	CCT3	2	3	CFAP53	CHRNA7	CLTCL1	P
CCDC186	CCT4	CDC5L	CEBPD	CFAP61	CHRNB1	CLU	COL4A5
CCDC187	CCT5	CDC7	CEBPZ	CFHR4	CHRNB2	CLUH	COL6A2
CCDC22	CCT6A	CDC73	CELSR1	CFL1	CHRNB4	CMAS	COL7A1
CCDC24	CCT6B	CDCA2	CELSR2	CFL2	CHRNA4	CMBL	COL9A2
CCDC28A	CCT7	CDCA3	CELSR3	CFTR	CHRNA6	CMIP	COL9A3
CCDC36	CCT8	CDCA5	CEMP1	CGA	CHST15	CMSS1	COLGALT
CCDC43	CD109	CDCA7L	CEND1	CGGBP1	CHUK	CMTM3	1
CCDC47	CD177	CDCA8	CENPA	CGN	CHURC1	CMTM5	COLQ
CCDC50	CD2	CDCP1	CENPB	CGRRF1	CIAO1	CMTM7	COMMD
CCDC57	CD22	CDH1	CENPE	CHAF1A	CIART	CMTM8	1
CCDC59	CD24	CDH10	CENPF	CHCHD2	CIB1	CMTR1	COMMD
CCDC61	CD247	CDH15	CENPJ	CHCHD3	CIB3	CMYA5	3-BMI1
CCDC7	CD27	CDH2	CENPO	CHCHD6	CIC	CNBP	COMT
CCDC77	CD2AP	CDH23	CENPP	CHD1L	CIDEA	CNDP2	COPA
CCDC8	CD2BP2	CDH3	CENPT	CHD2	CIRBP	CNGA3	COPB1
CCDC82	CD300C	CDH4	CENPU	CHD3	CISH	CNGB1	COPB2
CCDC85B	CD36	CDH5	CENPV	CHD4	CIT	CNIH2	COPE
CCDC85C	CD37	CDIPT	CEP104	CHD5	CKAP4	CNIH3	COPG1
CCDC88A	CD3D	CDK1	CEP112	CHD8	CKAP5	CNIH4	COPG2
CCDC88B	CD3E	CDK11A	CEP120	CHDH	CKB	CNKSRI	COPRS
CCDC90B	CD3EAP	CDK11B	CEP126	CHEK1	CKS1B	CNKSRI	COPS2
CCDC93	CD44	CDK13	CEP128	CHEK2	CLASP2	CNN3	COPS3
CCDC94	CD59	CDK15	CEP131	CHERP	CLCN2	CNNM3	COPS4
CCHCR1	CD63	CDK16	CEP135	CHFR	CLCN3	CNOT1	COPS5
CCK	CD81	CDK17	CEP152	CHGB	CLCN7	CNOT7	COPS6
CCKAR	CD9	CDK18	CEP162	CHKA	CLCNKB	CNP	COPS7A
CCKBR	CD93	CDK19	CEP170	CHM	CLDN12	CNPY2	COPS7B
CCL14	CD97	CDK2	CEP170P	CHML	CLEC17A	CNR1	COPS8
CCL21	CDAN1	CDK20	1	CHMP1A	CLEC1A	CNST	COPZ1
CCL22	CDC23	CDK2AP1	CEP19	CHMP1B	CLEC3B	CNTF	COQ10A
CCL28	CDC25A	CDK3	CEP192	CHMP2A	CLEC4D	CNTFR	COQ8A
CCM2L	CDC25B	CDK4	CEP250	CHMP2B	CLEC4G	CNTLN	CORO1B
CCNA2	CDC25C	CDK5	CEP290	CHMP3	CLEC4M	CNTN1	CORO1C
CCNB1	CDC27	CDK5R1	CEP295	CHMP4A	CLEC7A	CNTN2	CORO2A
CCNB1IP	CDC34	CDK5RAP	CEP350	CHMP4B	CLGN	CNTN3	CORO6
1	CDC37	2	CEP44	CHMP4C	CLIC1	CNTNAP1	CORO7
CCNC	CDC42	CDK5RAP	CEP55	CHMP5	CLIC5	CNTNAP2	COX1
CCND1	CDC42BP	3	CEP57L1	CHMP6	CLINT1	CNTNAP4	COX15
CCND2	A	CDK6	CEP63	CHN1	CLIP4	CNTRL	COX5A
CCND3	CDC42BP	CDK7	CEP68	CHN2	CLK2	CNTROB	COX5B
CCNDBP1	B	CDK9	CEP70	CHORDC	CLK3	COASY	COX6C
CCNE1	CDC42BP	CDKL3	CEP72	1	CLN3	COBL	CP
CCNE2	G	CDKL5	CEP76	CHPF	CLN5	COBLL1	CPA1
CCNH	CDC42EP	CDKN1A	CEP83	CHPT1	CLN6	COG2	CPE
CCNI	1	CDKN1B	CEP89	CHRD	CLNK	COG3	CPEB1
CCNK		CDKN2A	CEP95	CHRM1	CLNS1A	COG4	CPEB3

CPEB4	CSMD1	CTTNBP2	DAXX	DECR1	DLG2	DNMT3B	DTX2
CPLX1	CSMD2	NL	DAZAP2	DEFA1	DLG3	DNMT3L	DTX3
CPLX2	CSN2	CTXN3	DBF4B	DEFB124	DLG4	DNPEP	DTX3L
CPM	CSN3	CUEDC1	DBH	DENND1	DLG5	DNTTIP1	DUPD1
CPN1	CSNK1A1	CUL1	DBI	A	DLGAP1	DNTTIP2	DUSP12
CPNE1	CSNK1A1	CUL2	DBN1	DENND2	DLGAP2	DOC2B	DUSP15
CPNE2	L	CUL3	DBNL	A	DLGAP3	DOCK1	DUSP16
CPNE7	CSNK1D	CUL4A	DBR1	DENND4	DLGAP4	DOCK10	DUSP18
CPNE8	CSNK1E	CUL4B	DCAF11	A	DLK1	DOCK2	DUSP26
CPOX	CSNK1G1	CUL5	DCAF13	DENND4	DLK2	DOCK3	DUSP3
CPSF6	CSNK1G2	CUL9	DCAF7	C	DLST	DOCK6	DUSP9
CPSF7	CSNK1G3	CUTC	DCAKD	DEPDC1B	DLX4	DOCK7	DUX1
CPT1A	CSNK2A1	CWC15	DCBLD2	DERL2	DMBX1	DOCK8	DUX3
CPTP	CSNK2A2	CWC22	DCD	DES	DMC1	DOCK9	DUX4
CPXCR1	CSNK2B	CWC25	DCDC2	DEUP1	DMD	DOK1	DUX4L9
CRABP2	CSPG5	CWC27	DCLK1	DFFA	DMKN	DOK4	DVL1
CRADD	CSRNP1	CXADR	DCLK3	DFFB	DMRT1	DOK5	DVL2
CRAMP1	CSRNP2	CXCL1	DCP1A	DFNA5	DMRT3	DOK6	DVL3
CRB1	CSRNP3	CXCL11	DCTD	DGAT1	DMTN	DOK7	DYNC1H1
CRB3	CSRP1	CXCL2	DCTN1	DGAT2L6	DMWD	DOLK	DYNC1I1
CRCT1	CSRP2	CXCL5	DCTN2	DGCR6L	DMXL2	DOT1L	DYNC1I2
CREB1	CSRP3	CXCR2	DCTN3	DGCR8	DNAAF2	DPCD	DYNC1LI2
CREB3	CST2	CXCR4	DCTN4	DGKA	DNAAF5	DPCR1	DYNLL1
CREB3L1	CST6	CXXC1	DCUN1D	DGKE	DNAH1	DPF2	DYNLL2
CREB3L4	CST9L	CYB561D	1	DGKG	DNAH3	DPM1	DYNLRB1
CREB5	CSTA	1	DCUN1D	DGKH	DNAH7	DPM3	DYRK1A
CREBBP	CSTB	CYB5B	5	DGKI	DNAJA1	DPP3	DYRK1B
CRELD1	CT55	CYBRD1	DDB1	DGKZ	DNAJA2	DPP4	DYRK3
CRELD2	CTAG1A	CYC1	DDB2	DHCR24	DNAJA3	DPP7	DYRK4
CREM	CTAGE1	CYCS	DDC	DHCR7	DNAJB1	DPP9	DYSF
CRHR1	CTAGE5	CYFIP1	DDIT4	DHRS11	DNAJB11	DPPA2	DYX1C1
CRIM1	CTBP1	CYFIP2	DDIT4L	DHRS2	DNAJB12	DPPA4	DZIP3
CRIP1	CTBP2	CYLC2	DDN	DHX15	DNAJB13	DPY30	E2F3
CRIPT	CTCFL	CYLD	DDO	DHX16	DNAJB4	DPYD	E2F8
CRK	CTGF	CYP24A1	DDR1	DHX30	DNAJB5	DPYSL2	EAF1
CRKL	CTHRC1	CYP2E1	DDR2	DHX34	DNAJB6	DPYSL3	EBLN2
CRMP1	CTLA4	CYP39A1	DDX1	DHX36	DNAJC10	DPYSL4	ECD
CRNKL1	CTNNA1	CYP4F2	DDX11	DHX9	DNAJC11	DPYSL5	ECHDC1
CRP	CTNNA2	CYP4F8	DDX17	DIAPH1	DNAJC13	DQX1	ECHS1
CRTC1	CTNNA3	CYSLTR2	DDX20	DIAPH2	DNAJC21	DR1	ECM1
CRTC2	CTNNAL1	CYSRT1	DDX21	DIAPH3	DNAJC3	DRAP1	ECM29
CRTC3	CTNNB1	CYTH2	DDX24	DIDO1	DNAJC4	DRD2	ECSIT
CRY1	CTNNBIP	DAAM1	DDX27	DIEXF	DNAJC5	DRD4	ECT2
CRY2	1	DAAM2	DDX31	DIRAS2	DNAJC6	DRG1	EDARAD
CRYAA	CTNNBL1	DAB1	DDX39B	DIS3	DNAJC7	DROSHA	D
CRYAB	CTNND1	DAB2	DDX3X	DISC1	DNAJC8	DRP2	EDC3
CRYBA1	CTNND2	DAB2IP	DDX4	DISP3	DNAL4	DSCAML1	EDRF1
CRYBA2	CTPS1	DACT1	DDX41	DIXDC1	DNAL1	DSG2	EEA1
CRYBA4	CTPS2	DAD1	DDX42	DKC1	DNASE1L	DSN1	EEF1A1
CRYBB2	CTR9	DAG1	DDX47	DKFZp45	2	DSP	EEF1A2
CRYGC	CTSD	DAGLA	DDX49	1B226	DNM1	DST	EEF1B2
CSAD	CTSG	DALRD3	DDX5	DKFZp68	DNM1L	DSTN	EEF1D
CSE1L	CTSV	DAP3	DDX55	6J1593	DNM2	DTNA	EEF1E1
CSF1R	CTTN	DAPK1	DDX6	DKK1	DNM3	DTNB	EEF1G
CSF2RB	CTTNBP2	DAPK3	DDX60L	DKKL1	DNMBP	DTNBP1	EEF2
CSK		DAPP1	DEAF1	DLG1	DNMT1	DTX1	EEF2K



EEF2KMT	EIF4G1	EPHA7	EXOC1	FAM135B	FANCC	FERMT3	FLRT2
EFEMP1	EIF4G2	EPHA8	EXOC2	FAM160A	FANCD2	FES	FLRT3
EFEMP2	EIF4H	EPHB4	EXOC3	2	FANCF	FEZ1	FLT1
EFHC1	EIF5	EPM2AIP	EXOC4	FAM161A	FANCI	FEZ2	FLT3LG
EFHC2	EIF5A	1	EXOC5	FAM161B	FANCL	FGD5	FLYWCH1
EFHD1	EIF5B	EPN2	EXOC6	FAM162A	FAP	FGD6	FMNL1
EFHD2	EIF6	EPOR	EXOC6B	FAM163A	FARP1	FGF1	FMNL2
EFNA2	EIPR1	EPRS	EXOC7	FAM163B	FARS2	FGF10	FMNL3
EFNA4	ELAVL1	EPS15	EXOC8	FAM168A	FARSA	FGF12	FMOD
EFNA5	ELF3	EPS15L1	EXOSC10	FAM168B	FAS	FGF13	FMR1
EFNB1	ELF5	EPS8	EXOSC5	FAM171A	FASLG	FGF16	FN1
EFNB2	ELFN1	EPS8L2	EXOSC8	1	FASN	FGF2	FNBP1
EFNB3	ELFN2	EPSTI1	EXOSC9	FAM171A	FASTKD3	FGF23	FNDC3A
EFS	ELK1	ERBB2	EXT2	2	FASTKD5	FGF5	FNDC3B
EFTUD2	ELL	ERBB3	EXTL3	FAM171B	FAT1	FGF8	FOLH1
EGF	ELL2	ERBB4	EYA3	FAM173A	FATE1	FGFR1	FOPNL
EGFL6	ELMO1	ERBIN	EYA4	FAM188A	FAXDC2	FGFR1OP	FOS
EGFR	ELMSAN1	ERC1	EZH2	FAM189B	FBF1	FGFR1OP	FOSB
EGLN3	ELOA	ERC2	EZR	FAM192A	FBL	2	FOSL1
EGR1	ELOB	ERCC1	F11R	FAM207A	FBLIM1	FGFR2	FOSL2
EHBP1	ELOC	ERCC2	F13A1	FAM208A	FBLN1	FGR	FOXA3
EHD1	ELOVL7	ERCC3	F2R	FAM208B	FBN3	FHIT	FOXB1
EHD2	EMD	ERCC4	F2RL1	FAM20C	FBP1	FHL1	FOXC1
EHD3	EMILIN1	ERCC6L	F2RL2	FAM213B	FBP2	FHL2	FOXD4
EHD4	EML4	ERCC8	FA2H	FAM214B	FBXL15	FHL3	FOXD4L6
EHHADH	ENAH	ERG	FAAH	FAM218A	FBXL18	FHL5	FOXE1
EHMT2	ENG	ERGIC1	FAAP24	FAM219B	FBXL3	FHOD1	FOXF2
EID2B	ENGASE	ERH	FABP3	FAM22F	FBXL8	FIBP	FOXG1
EIF1	ENKD1	ERI1	FABP5	FAM234A	FBXO11	FIP1L1	FOXH1
EIF1AD	ENKUR	ERI3	FADD	FAM27E3	FBXO17	FIS1	FOXI2
EIF1B	ENO1	ERICH3	FADS6	FAM3C	FBXO18	FKBP14	FOXJ2
EIF2AK2	ENO1B	ERLIN1	FAF1	FAM46B	FBXO2	FKBP15	FOXK1
EIF2AK4	ENO2	ERLIN2	FAF2	FAM47A	FBXO21	FKBP1A	FOXK2
EIF2B1	ENO3	ERMN	FAH	FAM47B	FBXO22	FKBP1B	FOXL1
EIF2B2	ENOX1	ERP44	FAHD1	FAM49B	FBXO28	FKBP3	FOXMI
EIF2B3	ENPP1	ERRFI1	FAIM2	FAM50B	FBXO41	FKBP4	FOXO1
EIF2B4	ENPP2	ESCO2	FAM102A	FAM53C	FBXO45	FKBP5	FOXO3
EIF2B5	ENPP3	ESF1	FAM103A	FAM64A	FBXO46	FKBP6	FOXP1
EIF2S1	ENSA	ESR1	1	FAM65A	FBXO7	FKBP7	FOXP2
EIF3A	ENTPD6	ESR2	FAM107A	FAM65B	FBXO8	FKBP8	FOXP3
EIF3B	ENY2	ESRRA	FAM110A	FAM65C	FBXW11	FKBP9	FOXQ1
EIF3D	EOGT	ESRRG	FAM110B	FAM71C	FBXW5	FKBPL	FOXSI
EIF3E	EP300	ESX1	FAM110C	FAM71F1	FBXW7	FKSG66	FRAS1
EIF3F	EP400	ESYT1	FAM111B	FAM74A4	FCF1	FKSG83	FRAT1
EIF3G	EPAS1	ESYT2	FAM114A	FAM81B	FCGR2B	FLAD1	FRAT2
EIF3H	EPB41	ETFA	1	FAM83A	FCGR2C	FLG2	FRK
EIF3I	EPB41L1	ETHE1	FAM114A	FAM83B	FCHO1	FLI1	FRMD5
EIF3J	EPB41L2	ETNK2	2	FAM83D	FCHO2	FLII	FRMD6
EIF3K	EPB41L3	ETS1	FAM118B	FAM83F	FCHSD1	FLJ13057	FRMPD4
EIF3L	EPB41L4	ETV5	FAM120C	FAM83H	FCHSD2	FLJ34048	FRYL
EIF3S3	B	EVA1A	FAM122C	FAM86C1	FCRL2	FLNA	FSBP
EIF4A3	EPB41L5	EVC2	FAM124B	FAM90A1	FECH	FLNB	FSCN1
EIF4B	EPHA10	EVI5L	FAM127A	FAM98A	FEM1B	FLNC	FSD2
EIF4E	EPHA2	EVL	FAM129A	FAM9A	FEN1	FLOT1	FTH1
EIF4E2	EPHA3	EWSR1	FAM131C	FAM9B	FER	FLOT2	FTL
EIF4EBP1	EPHA4	EXO1	FAM134B	FANCA	FERMT2	FLRT1	FTSJ1

FUBP3	GALNT10	GGT6	GNB4	GPR3	GTF2I	HDAC8	HIST1H2B
FUCA2	GALNT12	GH1	GNB5	GPR39	GTF2IRD1	HDAC9	L
FUNDC1	GALNT2	GHDC	GNE	GPR45	GTF3A	HDGFRP2	HIST1H2B
FUNDC2	GALNT3	GHITM	GNG12	GPR63	GTF3C1	HDLBP	O
FUS	GALNT7	GHRH	GNG3	GPR98	GTF3C2	HEATR1	HIST1H3
FUT2	GAN	GHRL	GNG4	GPRASP1	GTF3C4	HECTD3	A
FUT9	GANAB	GID8	GNL2	GPRASP2	GTF3C5	HECTD4	HIST1H4
FXN	GAP43	GIGYF1	GNL3	GPRC5A	GTPBP2	HECW1	A
FXR1	GAPDH	GIGYF2	GNL3L	GPRC5D	GTSE1	HEL-S-	HIST2H2
FXR2	GAPDHS	GIMAP1	GNMT	GPS1	GUCD1	101	AA3
FXYD6	GAR1	GIMAP1-	GNPTAB	GRAP	GUCY1A2	HEL-S-42	HIST2H2
FYB	GAREM1	GIMAP5	GNS	GRAP2	GUCY1B3	HEL-S-70	AB
FYCO1	GAS2L2	GIMAP5	GOLGA1	GRASP	GUCY2D	HELLS	HIST2H2B
FYN	GAS2L3	GIMAP8	GOLGA2	GRB10	GUCY2F	HELZ	E
FZD2	GAS7	GIPC1	GOLGA4	GRB14	GULP1	HEMGN	HIVEP1
FZD3	GAS8	GIPC2	GOLGA5	GRB2	YG1	HERC2	HK1
FZD5	GATA1	GIT1	GOLGA6	GRB7	GYPC	HERC4	HLA-A
FZD6	GATA2	GIT2	A	GRHL2	GYS1	HERC5	HLA-B
FZD7	GATA3	GJA1	GOLGA6L	GRIA1	GZMB	HEXA	HLA-C
FZD8	GATAD2A	GJA4	9	GRIA2	H1FX	HEXDC	HLA-DMB
G2XKQO	GATAD2B	GJA5	GOLGA7	GRIA4	H2AFX	HEXIM1	HLA-
G3BP1	GBA	GJB5	GOLGA8	GRID2	H2AFY	HEXIM2	DPB1
G3BP2	GBAS	GKAP1	DP	GRIK2	H3BN98	HEYL	HLA-
GAB1	GBE1	GLB1L2	GOLGA8F	GRIK5	H3F3A	HGD	DQA1
GAB2	GBF1	GLCE	GOLGB1	GRIN1	HAAO	HGF	HLA-
GAB3	GBP2	GLI1	GOLIM4	GRIN2A	HABP4	HGS	DRB1
GABARAP	GCA	GLIPR1L2	GOLM1	GRIN2B	HACD1	HHATL	HLA-
GABARAP	GCAT	GLIS2	GOLPH3L	GRIN2C	HACD3	HHIP	DRB3
L1	GCC1	GLOD4	GOLT1B	GRIN2D	HACE1	HIC1	HLTF
GABARAP	GCDH	GLP1R	GOPC	GRIP1	HACL1	HIF1A	HMBOX1
L2	GCFC2	GLP2R	GORAB	GRIP2	HADHA	HIF1AN	HMBS
GABBR1	GCH1	GLRA1	GORASP2	GRIPAP1	HADHB	HIGD1A	HMG20A
GABBR2	GCLM	GLRA2	GOSR1	GRK2	HAP1	HIGD1C	HMGB1
GABPB1	GCM2	GLRB	GOSR2	GRK5	HAPLN2	HIKESHI	HMGB2
GABPB2	GCN1	GLRX3	GOT1	GRK6	HAUS1	HIN1L	HMG2N2
GABRA1	GCNT3	GLS2	GOT2	GRM1	HAUS5	HIP1	HMHA1
GABRA2	GDA	GLT8D1	GP6	GRM2	HAUS6	HIP1R	HMMR
GABRA3	GDF5	GLTSCR1	GPAA1	GRM5	HAVCR2	HIPK1	HMOX1
GABRA4	GDF9	GLTSCR1L	GPALPP1	GRN	HAX1	HIPK2	HMOX2
GABRA6	GDI1	GLTSCR2	GPANK1	GRXCR1	HBA1	HIPK3	HN1
GABRB1	GDI2	GLUD1	GPATCH1	GSE1	HBG2	HIPK4	HNF1A
GABRB2	GEM	GLUL	1	GSG1L	HBP1	HIST1H1	HNF4A
GABRB3	GEMIN4	GLYAT	GPATCH2	GSK3A	HCCS	A	HNMT
GABRD	GEMIN7	GLYCTK	GPATCH8	GSK3B	HCK	HIST1H1C	HNRNPA
GABRQ	GEMIN8	GLYR1	GPBP1	GSKIP	HCLS1	HIST1H1E	0
GABRR1	GET4	GMCL1P1	GPBP1L1	GSN	HCN2	HIST1H1T	HNRNPA
GAD1	GFAP	GMEB2	GPC4	GSTK1	HCN4	HIST1H2	1
GAD2	GFER	GNA13	GPD1	GSTM3	HCRT	AA	HNRNPA
GADD45	GFI1	GNAI1	GPBR1	GSTP1	HDAC1	HIST1H2	2B1
A	GFI1B	GNAI2	GPHN	GSTT1	HDAC11	AG	HNRNPA
GADD45	GFM2	GNAI3	GPKOW	GSTZ1	HDAC2	HIST1H2B	3
G	GGA1	GNAO1	GPM6A	GTF2B	HDAC3	B	HNRNPA
GADD45	GGA2	GNAQ	GPM6B	GTF2E2	HDAC4	HIST1H2B	B
GIP1	GGA3	GNAS	GPR108	GTF2F1	HDAC5	C	HNRNPC
GAK	GGCT	GNB1	GPR12	GTF2F2	HDAC6	HIST1H2B	HNRNPD
GALC	GGN	GNB2	GPR135	GTF2H5	HDAC7	H	

HNRNPD	HSD3B7	ID2	ILK	ITGA3	KBTBD3	KIAA0324	KLHL13
L	HSF1	ID4	ILKAP	ITGA4	KBTBD7	KIAA0408	KLHL15
HNRNPF	HSF2	IDH3A	ILVBL	ITGA5	KCNA1	KIAA0430	KLHL18
HNRNPH	HSF2BP	IDO2	IMMT	ITGA6	KCNA10	KIAA0753	KLHL22
1	HSFY1	IDS	IMPACT	ITGAV	KCNA2	KIAA0907	KLHL24
HNRNPH	HSP90AA	IER3	IMPDH2	ITGB1	KCNA3	KIAA1109	KLHL35
2	1	IER3IP1	INA	ITGB1BP1	KCNA4	KIAA1191	KLHL38
HNRNPH	HSP90AB	IER5	INADL	ITGB2	KCNA5	KIAA1217	KLHL42
3	1	IFI16	INCA1	ITGB3	KCNA6	KIAA1328	KLHL7
HNRNPK	HSP90B1	IFI30	INF2	ITGB3BP	KCNAB1	KIAA1429	KLHL9
HNRNPL	HSPA12A	IFIT3	ING2	ITGB4	KCNAB2	KIAA1522	KLK6
HNRNPLL	HSPA1A	IFNG	ING4	ITGB5	KCNB1	KIAA1549	KLK8
HNRNPM	HSPA1L	IFNGR1	ING5	ITGB7	KCNB2	KIAA1683	KLRC1
HNRNPR	HSPA2	IFNGR2	INO80B	ITK	KCNC4	KIAA1958	KMT2B
HNRNPU	HSPA4	IFT140	INO80B-	ITM2C	KCND2	KIDINS22	KMT5C
HNRNPU	HSPA5	IFT20	WBP1	ITPKA	KCNE1	0	KNG1
L1	HSPA6	IFT22	INO80E	ITPR1	KCNF1	KIF11	KNL1
HOGA1	HSPA7	IFT57	INPP5B	ITPR2	KCNH1	KIF13B	KNSTRN
HOMER1	HSPA8	IGF1R	INPP5D	ITPR3	KCNIP1	KIF14	KNTC1
HOMER2	HSPA9	IGF2BP1	INPP5E	ITSN1	KCNIP2	KIF16B	KPNA1
HOMER3	HSPB1	IGF2BP2	INPP5J	ITSN2	KCNIP3	KIF17	KPNA2
HOMEZ	HSPB2	IGF2BP3	INPL1	IVNS1AB	KCNJ10	KIF18A	KPNA3
HOOK2	HSPB6	IGF2R	INSC	P	KCNJ12	KIF1A	KPNA4
HOPX	HSPB8	IGFBP3	INSR	IWS1	KCNJ16	KIF1B	KPNA6
HOXA1	HSPBAP1	IGHA1	INTS2	JADE1	KCNJ2	KIF1C	KPNB1
HOXA3	HSPBP1	IGHG1	INTU	JADE2	KCNJ4	KIF21B	KPRP
HOXA5	HSPD1	IGHG3	INVS	JAG1	KCNK1	KIF22	KRAS
HOXB5	HSPE1	IGHM	IP6K1	JAG2	KCNK10	KIF23	KRBA1
HOXC10	HSPG2	IGIP	IPO4	JAGN1	KCNN2	KIF26A	KRT1
HOXC4	HSPH1	IGKC	IPO5	JAK1	KCNN4	KIF26B	KRT10
HOXC6	HTATSF1	IGKV1-5	IPO7	JAK2	KCNQ1	KIF2A	KRT13
HOXC8	HTR1B	IGLL1	IQCB1	JAK3	KCTD1	KIF2C	KRT14
HP1BP3	HTR1E	IGSF21	IQCE	JAM2	KCTD12	KIF3A	KRT15
HPCA	HTR2A	IGSF22	IQCG	JAML	KCTD13	KIF3B	KRT16
HPCAL1	HTR2B	IGSF9	IQGAP1	JMJD7	KCTD17	KIF3C	KRT17
HPN	HTR2C	IK	IQGAP2	JMY	KCTD2	KIF5A	KRT19
HPRT1	HTR3A	IKBKAP	IQGAP3	JOSD1	KCTD20	KIF5B	KRT20
HPS4	HTR3B	IKBKB	IQSEC1	JPH3	KCTD21	KIF5C	KRT24
HPSE	HTR3C	IKBKE	IQSEC2	JRK	KCTD3	KIF9	KRT27
HRAS	HTR3D	IKBKG	IRAK1	JUN	KCTD5	KIFAP3	KRT31
HRASLS5	HTR3E	IKZF1	IRAK1BP1	JUNB	KCTD6	KIFC1	KRT33B
HRG	HTR6	IKZF2	IRAK2	JUND	KCTD8	KIFC2	KRT34
HRH3	HTR7	IKZF3	IRF2	JUP	KCTD9	KIFC3	KRT35
HRK	HTRA2	IL13RA2	IRF3	KALRN	KDELR1	KIR3DL1	KRT36
HRSP12	HTT	IL15RA	IRF4	KANK1	KDM1A	KIRREL2	KRT37
HS1BP3	HUNK	IL16	IRF7	KANK2	KDM3B	KIRREL3-	KRT38
HS6ST2	HUWE1	IL18	IRF8	KANK4	KDM4A	AS3	KRT40
HSCB	HYAL3	IL1A	IRS1	KANSL1	KDM5B	KIT	KRT5
HSD17B1	HYDIN	IL1RAPL1	IRS2	KAT2B	KDR	KLC1	KRT6A
0	HYOU1	IL24	IRS4	KAT5	KERA	KLC2	KRT73
HSD17B1	HYPM	IL31RA	ISCU	KAT6B	KHDRBS1	KLC3	KRT75
2	IBTK	IL3RA	ISG20L2	KAT7	KHDRBS2	KLF4	KRT76
HSD17B1	ICA1	IL6	IST1	KATNA1	KHDRBS3	KLF8	KRT8
4	ICAM1	IL6ST	ITCH	KATNAL2	KHK	KLHDC2	KRT82
HSD17B4	ICAM5	ILF2	ITGA1	KATNBL1	KHSRP	KLHDC3	KRT85
HSD17B7	ID1	ILF3	ITGA2	KAZN	KIAA0141	KLHDC8B	KRTAP1-1

KRTAP1-5	L3MBTL2	LCP2	LMTK2	LTB4R2	MAP1B	MAPRE1	MECOM
KRTAP10-6	L3MBTL3	LCT	LMTK3	LTBP1	MAP1LC3	MAPRE2	MECP2
	L3MBTL4	LDHA	LNPEP	LTBP2	A	MAPRE3	MED1
KRTAP10-7	LAMA2	LDHAL6A	LNK1	LTBP3	MAP1LC3	MAPT	MED12
	LAMA4	LDHB	LOC3898	LTBP4	B	MARCH1	MED12L
KRTAP10-8	LAMA5	LDLR	34	LUC7L2	MAP1LC3	0	MED14
	LAMB1	LDLRAD1	LOC4012	LUC7L3	C	MARCH3	MED19
KRTAP10-9	LAMB2	LDOC1	96	LURAP1	MAP1S	MARCH9	MED21
	LAMC1	LEF1	LOC6429	LUZP1	MAP2	MARK2	MED24
KRTAP11-1	LAMP1	LEFTY2	47	LXN	MAP2K1	MARK3	MED25
	LAMP2	LEMD3	LONP1	LY6G6C	MAP2K2	MARK4	MED27
KRTAP12-3	LAMTOR	LENG1	LONRF1	LYAR	MAP2K3	MARS	MED28
	1	LENG8	LONRF3	LYN	MAP2K4	MASP1	MED29
KRTAP13-2	LAMTOR	LEO1	LPAR1	LYST	MAP2K5	MASP2	MED31
	3	LEPROTL	LPCAT1	LZTFL1	MAP2K6	MAST1	MED4
KRTAP13-3	LAMTOR	1	LPIN2	LZTS1	MAP2K7	MAST2	MED8
	4	LETM1	LPIN3	LZTS2	MAP3K1	MAST3	MEF2A
KRTAP15-1	LAMTOR	LGALS1	LRBA	LZTS3	MAP3K11	MAT2A	MEF2C
	5	LGALS14	LRCH2	M1AP	MAP3K12	MATK	MEF2D
KRTAP17-1	LANCL1	LGALS3	LRCH4	MAB21L3	MAP3K14	MATN2	MEGF10
	LANCL2	LGALS3B	LRFN1	MACF1	MAP3K3	MATR3	MEGF6
KRTAP19-1	LAP3	P	LRFN4	MAD1L1	MAP3K4	MAU2	MEGF8
	LAPTM4B	LGALS8	LRIF1	MAD2L1	MAP3K5	MAVS	MEIS1
KRTAP19-3	LAPTM5	LGALS9B	LRP1	MAD2L1	MAP3K7	MAX	MEIS2
	LARP1	LGALS9C	LRP11	BP	MAP3K7	MAZ	MELK
KRTAP19-5	LAS1L	LGI3	LRP12	MADD	CL	MB21D2	MEMO1
	LASP1	LHX2	LRP1B	MAEA	MAP3K8	MBD1	MEN1
KRTAP19-7	LAT	LIG3	LRP2	MAF1	MAP4	MBD2	MEOX1
	LATS1	LIMA1	LRP4	MAFG	MAP4K1	MBD3	MEOX2
KRTAP2-3	LAX1	LIMCH1	LRP6	MAGEA1	MAP4K3	MBD6	MEPE
KRTAP23-1	LBP	LIMK1	LRP8	1	MAP4K4	MBIP	MESDC1
	LBR	LIMK2	LRPAP1	MAGEA2	MAP4K5	MBNL1	MESDC2
KRTAP26-1	LCA5	LIMS1	LRPPRC	MAGEA3	MAP7D1	MBNL3	MET
	LCA5L	LIMS2	LRR1	MAGEA4	MAPK1	MBOAT1	METTL17
KRTAP3-2	LCE1A	LIMS3	LRR14	MAGEA6	MAPK10	MBOAT7	METTL21
KRTAP3-3	LCE1B	LIN28A	LRR14	MAGEB2	MAPK12	MBP	A
KRTAP4-11	LCE1C	LIN37	LRR14	MAGEB4	MAPK13	MBTPS1	METTL23
	LCE1D	LIN54	LRR14	MAGED1	MAPK14	MCC	METTL3
KRTAP4-2	LCE1E	LIN7A	LRR14	MAGED2	MAPK1IP	MCF2L	METTL7A
KRTAP4-5	LCE1F	LIN7B	LRR14	MAGED4	1L	MCM10	MEX3C
KRTAP5-11	LCE2A	LIN7C	LRR14	B	MAPK3	MCM2	MFAP1
	LCE2B	LINC0023	LRR14	MAGEE1	MAPK4	MCM3	MFF
KRTAP5-2	LCE2C	8	LRR14	MAGI1	MAPK6	MCM3AP	MFN2
KRTAP5-3	LCE2D	LINGO1	LRR14	MAGI2	MAPK7	MCM4	MFSD6
KRTAP5-4	LCE3A	LITAF	LRR14	MAGI3	MAPK8	MCM5	MGA
KRTAP5-6	LCE3B	LLGL1	LRR14	MAGOH	MAPK8IP	MCM6	MGARP
KRTAP5-7	LCE3C	LLGL2	LRR14	MAGOH	1	MCM7	MGC163
KRTAP5-9	LCE3D	LMAN2L	LRR14	MAL	MAPK8IP	MCRS1	85
KRTAP6-1	LCE3E	LMNA	LRR14	MAL2	2	MCU	MGEA5
KRTAP6-2	LCE4A	LMNB1	LRR14	MALL	MAPK9	MDFI	MGME1
KRTAP8-1	LCE5A	LMNB2	LSM11	MALT1	MAPKAP	MDH1	MGST3
KRTAP9-2	LCK	LMO1	LSM2	MAN1B1	1	MDM1	MIA3
KSR1	LCLAT1	LMO2	LSM4	MANBAL	MAPKAP	MDM2	MIB1
KTN1	LCMT2	LMO3	LSM7	MANF	K2	MDM4	MIB2
KXD1	LCN2	LMO4	LSM8	MAOB	MAPKAP	MDN1	MIC13
L3MBTL1	LCOR	LMO7	LSS	MAP1A	K3	MEA1	MICAL1

MICAL3	MPDZ	MSRB3	MYH10	NANOS1	NDUFA5	NEUROD	NME2
MICALL1	MPG	MSS51	MYH14	NANS	NDUFA6	4	NME7
MICALL2	MPHOSP	MT-ATP8	MYH3	NAP1L1	NDUFA7	NEUROG	NMNAT1
MID1IP1	H10	MT-CO3	MYH7	NAP1L4	NDUFA8	2	NMU
MID2	MPHOSP	MT-ND2	MYH9	NAP1L5	NDUFA9	NEXN	NNT
MIEF1	H6	MT-ND5	MYL1	NAPA	NDUFAF1	NF1	NOA1
MIEF2	MPP1	MT1A	MYL12A	NAPB	NDUFAF3	NF2	NOB1
MIF	MPP2	MT3	MYL12B	NAPG	NDUFAF4	NFASC	NOC2L
MIF4GD	MPP3	MTA1	MYL6	NARF	NDUFAF5	NFATC2	NOC4L
MIIP	MPP5	MTA2	MYL6B	NARFL	NDUFAF7	NFATC2IP	NOD1
MINK1	MPP6	MTA3	MYL7	NAT1	NDUFB4	NFATC4	NOL4
MIP	MPP7	MTCH1	MYL9	NAT14	NDUFB7	NFE2	NOL4L
MIPEP	MPPED1	MTDH	MYLK	NAT9	NDUFB8	NFKB1	NOLC1
MIS18A	MPRIIP	MTERF1	MYLK2	NATD1	NDUFB9	NFKB2	NOM1
MISP	MPST	MTERF3	MYO10	NAV1	NDUFS1	NFKBIA	NOMO2
MKI67	MPZL1	MTF2	MYO15A	NBAS	NDUFS2	NFKBIB	NONO
MKKS	MRC2	MTG1	MYO16	NBEA	NDUFS3	NFKBID	NOP10
MKLN1	MRE11	MTHFD1	MYO18A	NBL1	NDUFS5	NFKBIE	NOP56
MKNK1	MRFAP1	MTHFD1L	MYO19	NBR1	NDUFS6	NFRKB	NOP58
MKNK2	MRFAP1L	MTHFD2	MYO1B	NCBP1	NDUFS7	NFS1	NOP9
MKRN3	1	MTHFR	MYO1C	NCBP2	NDUFS8	NFXL1	NOS1
MKS1	MRGBP	MTM1	MYO1D	NCF1	NDUFV2	NFYC	NOS1AP
MLANA	MRI1	MTMR10	MYO1E	NCF2	NDUFV3	NGEF	NOS3
MLEC	MRNIP	MTMR12	MYO5A	NCK1	NEB	NGF	NOSTRIN
MLF1	MROH1	MTMR2	MYO5B	NCK2	NEBL	NGFR	NOTCH1
MLH1	MRPL1	MTNR1A	MYO5C	NCKAP1	NECAB2	NHP2	NOTCH2
MLH3	MRPL10	MTNR1B	MYO6	NCKAP5	NECAP1	NHS	NL
MLK4	MRPL11	MTOR	MYO7A	NCKAP5L	NECAP2	NHSL1	NOTCH4
MLLT10	MRPL18	MTPN	MYO9A	NCKIPSD	NECTIN1	NHSL2	NOXA1
MLLT3	MRPL20	MTRR	MYO9B	NCL	NECTIN2	NIF3L1	NPAS2
MLLT6	MRPL22	MTSS1	MYOCD	NCLN	NECTIN3	NIFK	NPBWR2
MLPH	MRPL4	MTURN	MYOF	NCOA1	NECTIN4	NIN	NPEPPS
MME	MRPL43	MTUS2	MYOM1	NCOA2	NEDD4	NINJ2	NPFF
MMGT1	MRPL44	MTX2	MYOM2	NCOA3	NEDD4L	NINL	NPHP1
MMP1	MRPL57	MUC1	MYOT	NCOA4	NEDD8	NIPSNAP	NPHP4
MMP14	MRPL58	MUC12	MYOZ1	NCOA5	NEDD9	1	NPHS1
MMP9	MRPS18A	MUC13	MYOZ2	NCOR1	NEFH	NIPSNAP	NPM1
MMS19	MRPS25	MUC7	MYPN	NCS1	NEFL	3A	NPPB
MMTAG2	MRPS26	MUL1	MYPOP	NCSTN	NEFM	NISCH	NPRL2
MN1	MRPS33	MUM1	MYRIP	NDC80	NEK1	NKD1	NPTN
MNAT1	MRPS9	MUSK	MYT1L	NDE1	NEK2	NKD2	NPVF
MNDA	MRRF	MVD	N4BP1	NDEL1	NEK4	NKG7	NQO1
MNS1	MRVI1	MYB	N4BP3	NDFIP2	NEK6	NKRF	NQO2
MNT	MS4A13	MYBBP1	NAA10	NDN	NEK8	NKTR	NR0B2
MOAP1	MS4A3	A	NAA11	NDP	NELFB	NKX2-1	NR1D1
MOB1A	MSANTD	MYBPC2	NAA38	NDRG1	NELFCD	NKX2-2	NR1H2
MOB3B	2	MYBPHL	NAAA	NDRG2	NELFE	NLGN1	NR2E1
MOB3C	MSANTD	MYC	NAALADL	NDRG4	NELL1	NLGN3	NR2F6
MOB4	3	MYCBP	2	NDUFA10	NELL2	NLGN4X	NR3C1
MOG5	MSGN1	MYCBP2	NAB2	NDUFA11	NEMF	NLK	NR3C2
MORC3	MSH2	MYCBPA	NACA	NDUFA12	NET1	NLRP1	NR4A1
MORF4L1	MSH3	P	NACC2	NDUFA13	NETO2	NLRP12	NR5A1
MORF4L2	MSH5	MYCN	NADK	NDUFA2	NEU4	NLRP2	NRAP
MORN3	MSL1	MYD88	NAF1	NDUFA4	NEURL1	NLRP3	NRAS
MORN4	MSN	MYDGF	NALCN	NDUFA4L	NEURL4	NLRX1	NRBP1
MOS	MSRB2	MYH1	NAMPT	2		NMB	NRCAM

NRDC	NUP54	OXCT1	PARK7	PDCD7	PFDN6	PIH1D3	PLEKHG3
NRG1	NUP62	OXER1	PARP1	PDCL	PFKFB1	PIK3AP1	PLEKHG4
NRGN	NUP88	OXSR1	PARP10	PDCL3	PFKFB3	PIK3C2A	PLEKHH3
NRIP1	NUP93	OXT	PARP12	PDE12	PFKFB4	PIK3C2B	PLEKHN1
NRM	NUTM1	P2RX1	PARP2	PDE2A	PFKP	PIK3CG	PLEKHO1
NRXN1	NVL	P2RX4	PARVA	PDE4A	PFN1	PIK3R1	PLG
NRXN2	NXN	P2RX5	PARVB	PDE4B	PFN2	PIK3R2	PLIN3
NRXN3	NXPE2	P2RX6	PARVG	PDE4C	PGAM1	PIK3R3	PLK1
NSD2	NXPH3	P2RX7	PASK	PDE4D	PGAM5	PIKFYVE	PLK2
NSD3	OARD1	P2RY1	PATJ	PDE4DIP	PGAP2	PIM1	PLK3
NSDHL	OAZ1	P3H1	PATL1	PDE6D	PGK1	PIM2	PLK4
NSF	OBSCN	P450-	PAUF	PDE6G	PGM2L1	PIM3	PLN
NSFL1C	OCIAD1	CYP21B	PAWR	PDF	PGM3	PIN1	PLP1
NSG1	OCRL	P4HA3	PAX3	PDGFRA	PGR	PIN4	PLP2
NSL1	ODF2	P4HB	PAX6	PDGFRB	PGRMC1	PINK1	PLPP3
NSMCE2	ODF3B	P62988	PAX7	PDHB	PGRMC2	PINX1	PLPP4
NSMF	OFCC1	PA2G4	PAX8	PDIA2	PGS1	PIP4K2A	PLPP6
NSUN2	OFD1	PAAF1	PAXIP1	PDIA3	PHACTR1	PIP4K2B	PLPPR3
NSUN4	OGN	PABPC1	PBDC1	PDIA4	PHACTR2	PIP4K2C	PLS1
NT5C3A	OGT	PABPC3	PBK	PDIA5	PHACTR3	PIP5K1A	PLXNA2
NT5DC3	OIP5	PABPC4	PBRM1	PDK1	PHAX	PITX2	PLXNA3
NTF4	OLFM1	PABPC4L	PBX2	PDK2	PHB	PJA2	PLXNB1
NTM	OLFM2	PACS1	PBX3	PDK3	PHB2	PKD1	PLXNB2
NTNG1	OLFM3	PACSIN1	PBX4	PDLIM2	PHC1	PKM	PLXNB3
NTNG2	OLFML3	PACSIN2	PBXIP1	PDLIM3	PHF19	PKMYT1	PM20D2
NTPCR	OLIG1	PACSIN3	PC	PDLIM5	PHF20	PKN1	PMAIP1
NTRK1	OLIG3	PADI4	PCBD1	PDLIM7	PHF20L1	PKN2	PMEP1A
NTRK2	OLR1	PAFAH1B	PCBP1	PDPK1	PHF21A	PKN3	PMF1
NTS	OPA1	1	PCBP2	PDRG1	PHF5A	PKNOX2	PML
NTSR1	OPHN1	PAFAH1B	PCDH10	PDS5A	PHF7	PKP1	PMM1
NUAK1	OPRD1	2	PCDH11X	PDX1	PHF8	PKP2	PMPCA
NUAK2	OPRK1	PAFAH1B	PCDH15	PDXDC1	PHGDH	PKP4	PMS2
NUCKS1	OPRM1	3	PCDH8	PDXP	PHKA2	PLA1A	PNISR
NUDC	OPTN	PAG1	PCDHA13	PDZD11	PHKG2	PLA2G12	PNKD
NUDCD2	OR1D2	PAGR1	PCDHB12	PDZD2	PHLDA1	A	PNKP
NUDCD3	OR2AG1	PAICS	PCDHGA7	PDZK1	PHLDA3	PLA2G6	PNLIPRP1
NUDT18	OR3A1	PAK1	PCGF1	PDZK1IP1	PHLDB2	PLAC8	PNMA1
NUDT21	ORC1	PAK2	PCGF3	PDZRN3	PHLDB3	PLAC8L1	PNMA2
NUDT22	ORC5	PAK3	PCGF6	PEA15	PHLPP1	PLAUR	PNMA3
NUDT3	ORM1	PAK4	PCID2	PEAK1	PHLPP2	PLCB1	PNMA5
NUDT5	OSBP2	PAK5	PCIF1	PEBP1	PHRF1	PLCB4	PNN
NUDT9	OSBPL2	PAK6	PCLO	PEBP4	PI4K2A	PLCD3	PNO1
NUF2	OSBPL3	PALLD	PCM1	PECAM1	PI4K2B	PLCG1	PNP
NUFIP1	OSBPL6	PALM	PCMT1	PEF1	PI4KA	PLCG2	PNPLA2
NUFIP2	OSBPL9	PALMD	PCNA	PELI1	PI4KB	PLCH1	PNPLA6
NUMA1	OSGEP	PAM	PCNT	PELI2	PIAS1	PLCL2	POC1A
NUMB	OSGIN1	PAM16	PCNX3	PENK	PIAS2	PLD1	POC1B
NUMBL	OSR2	PANK2	PCNX4	PER3	PIAS3	PLD2	POC5
NUP107	OSTCL	PANX1	PCSK5	PES1	PIAS4	PLD3	POF1B
NUP133	OTUB1	PAPD4	PCSK6	PEX14	PIBF1	PLEC	POGZ
NUP153	OTUB2	PAPSS1	PCYT1A	PEX19	PICALM	PLEKHA1	POLA2
NUP155	OTUD4	PARD3	PDCD10	PEX5	PICK1	PLEKHA2	POLD1
NUP160	OTUD7B	PARD6A	PDCD2	PFAS	PID1	PLEKHA5	POLDIP2
NUP205	OTX1	PARD6B	PDCD4	PFDN1	PIEZO1	PLEKHA7	POLDIP3
NUP37	OTX2	PARD6G	PDCD5	PFDN2	PIH1D1	PLEKHB1	POLE
NUP50	OXA1L	PARK2	PDCD6IP	PFDN5	PIH1D2	PLEKHF2	POLG

POLG2	PPM1G	PPP2R2B	PRKCE	PRX	PTBP3	PTPRT	QARS
POLI	PPM1H	PPP2R4	PRKCG	PS1TP5B	PTCD3	PTRF	QKI
POLK	PPOX	PPP2R5A	PRKCI	P1	PTCH1	PTRH1	QPCTL
POLL	PPP1CA	PPP2R5B	PRKCQ	PSD	PTCH2	PTS	QRICH1
POLQ	PPP1CB	PPP2R5C	PRKCSH	PSD3	PTDSS1	PTTG1IP	QSER1
POLR1A	PPP1CC	PPP2R5D	PRK CZ	PSEN1	PTEN	PUF60	RAB10
POLR1B	PPP1R10	PPP2R5E	PRKD2	PSEN2	PTGDS	PUM1	RAB11A
POLR1C	PPP1R11	PPP3CA	PRKD3	PSIP1	PTGER2	PUS7L	RAB11B
POLR1D	PPP1R12	PPP3CB	PRKDC	PSMA1	PTGER3	PWWP2B	RAB11FIP
POLR1E	A	PPP3CC	PRKG1	PSMA2	PTGES3	PXDC1	1
POLR2A	PPP1R12	PPP3R1	PRKRA	PSMA3	PTGS1	PXN	RAB11FIP
POLR2B	B	PPP4R1	PRKRIP1	PSMA4	PTGS2	PYCARD	2
POLR2E	PPP1R12	PPP4R2	PRKX	PSMA5	PTH1R	PYCR1	RAB11FIP
POLR2G	C	PPP4R3A	PRLHR	PSMA6	PTH2R	PYGB	5
POLR2H	PPP1R13	PPP5C	PRMT1	PSMA7	PTK2	PYGL	RAB12
POLR2L	B	PPP6C	PRMT5	PSMB1	PTK2B	PYGM	RAB13
POLR3A	PPP1R13	PPP6R1	PRMT6	PSMB10	PTK6	PYGO1	RAB14
POLR3B	L	PPT1	PRMT9	PSMB2	PTK7	PYHIN1	RAB18
POLR3C	PPP1R14	PPTC7	PRNP	PSMB3	PTMA	PYM1	RAB1A
POM121	A	QGBP1	PROCR	PSMB4	PTN	Q00005-	RAB1B
POMP	PPP1R14	PR	PROP1	PSMB5	PTOV1	7	RAB21
PON2	B	PRAF2	PROSER2	PSMB6	PTP4A1	Q05193-	RAB22A
POP1	PPP1R15	PRAM1	PROX1	PSMB7	PTP4A2	5	RAB23
POSTN	A	PRAMEF4	PRPF18	PSMB9	PTP4A3	Q12914	RAB24
POT1	PPP1R15	PRC1	PRPF19	PSMC1	PTPN1	Q2VIK8	RAB26
POTEH	B	PRCC	PRPF3	PSMC2	PTPN11	Q53FC7	RAB27A
POTEKP	PPP1R16	PRCP	PRPF31	PSMC3	PTPN12	Q53G25	RAB27B
POU2F1	A	PRDM1	PRPF38A	PSMC4	PTPN13	Q53GZ6	RAB29
POU3F3	PPP1R18	PRDM14	PRPF38B	PSMC5	PTPN14	Q53HF2	RAB2A
POU6F2	PPP1R1B	PRDM16	PRPF4	PSMC6	PTPN18	Q59EJ3	RAB2B
PPA2	PPP1R2	PRDM4	PRPF40A	PSMD1	PTPN2	Q59EY7	RAB32
PPARG	PPP1R21	PRDX1	PRPF4B	PSMD10	PTPN21	Q59G22	RAB33A
PPBP	PPP1R26	PRDX2	PRPF6	PSMD11	PTPN22	Q59GP6	RAB35
PPEF1	PPP1R27	PRDX3	PRPH	PSMD12	PTPN23	Q59GR8	RAB37
PPEF2	PPP1R2P	PRDX4	PRPSAP1	PSMD13	PTPN3	Q5JPT6	RAB39A
PPFIA1	3	PRELP	PRPSAP2	PSMD14	PTPN4	Q5TCZ1-1	RAB39B
PPFIA2	PPP1R2P	PREX1	PRR10	PSMD2	PTPN5	Q5TCZ1-2	RAB3A
PPFIA3	9	PREX2	PRR12	PSMD3	PTPN6	Q5W150	RAB3B
PPFIA4	PPP1R32	PRG4	PRR13	PSMD4	PTPN7	Q6ZSR9	RAB3C
PPFIBP2	PPP1R35	PRICKLE3	PRR14	PSMD5	PTPN9	Q7KZQ1	RAB3GAP
PPHLN1	PPP1R36	PRKAA1	PRR16	PSMD6	PTPRA	Q7Z783	1
PPIA	PPP1R37	PRKAA2	PRR20C	PSMD7	PTPRB	Q8N779	RAB3IL1
PPIB	PPP1R3B	PRKAB1	PRR20D	PSMD8	PTPRC	Q8NBB2	RAB3IP
PPID	PPP1R3C	PRKAB2	PRR3	PSMD9	PTPRD	Q8TCT1	RAB40A
PPIF	PPP1R3D	PRKACA	PRR35	PSME3	PTPRE	Q8TE30	RAB40B
PPIG	PPP1R3E	PRKACB	PRR5	PSMF1	PTPRF	Q96BE0	RAB40C
PPIL2	PPP1R3G	PRKACG	PRR7	PSMG1	PTPRG	Q9BRL8	RAB4A
PPIL3	PPP1R7	PRKAG2	PRRC2A	PSORS1C	PTPRJ	Q9H1R2-	RAB5A
PPIL4	PPP1R8	PRKAR1A	PRRC2B	2	PTPRK	3	RAB5B
PPIP5K2	PPP1R9A	PRKAR1B	PRRC2C	PSPC1	PTPRM	Q9H8E5	RAB5C
PPL	PPP1R9B	PRKAR2A	PRRT2	PSPH	PTPRN	Q9H9I0	RAB6A
PPM1A	PPP2CA	PRKAR2B	PRSS1	PSRC1	PTPRN2	Q9HA55	RAB6B
PPM1B	PPP2CB	PRKCA	PRSS12	PSTPIP1	PTPRO	Q9HAA0	RAB6C
PPM1D	PPP2R1A	PRKCB	PRSS23	PTAFR	PTPRQ	Q9HAV2	RAB7A
PPM1E	PPP2R1B	PRKCD	PRTFDC1	PTBP1	PTPRR	Q9NWL9	RAB8A
PPM1F	PPP2R2A	PRKCDBP	PRUNE	PTBP2	PTPRS	Q9UL80	RAB8B

RABAC1	RARA	RBSN	RHOXF2	RNPC4	RPL41	RPS8	S100A6
RABEP1	RARB	RBX1	RHPN1	RNPS1	RPL5	RPS9	S100A9
RABEP2	RARS2	RC3H1	RIC8A	ROBO2	RPL6	RPSA	S100B
RABEPK	RASA1	RCAN3	RICTOR	ROBO3	RPL7	RPTOR	S100P
RABGAP1	RASAL2	RCBTB2	RIF1	ROCK1	RPL7A	RRAGB	SACS
RABGAP1	RASAL3	RCHY1	RILP	ROGDI	RPL7L1	RRAS	SAE1
L	RASD2	RCN1	RIMBP2	ROPN1	RPL8	RRAS2	SAFB
RABGEF1	RASGRF1	RCN2	RIMS1	ROR1	RPL9	RREB1	SAFB2
RABGGTA	RASGRP1	RCOR1	RIMS2	ROR2	RPLP0	RRP12	SAG
RABGGTB	RASGRP2	RCOR2	RIMS3	RORA	RPLP1	RRP1B	SAMD4A
RABIF	RASIP1	RCOR3	RIMS4	RORC	RPLP2	RRP8	SAMD9
RABL3	RASL10B	RDH11	RIN1	RP1L1	RPN1	RS1	SAMD9L
RABL6	RASSF1	RECQL5	RIN2	RPA1	RPN2	RSBN1	SAMHD1
RAC1	RASSF10	REEP3	RIN3	RPA2	RPP14	RSBN1L	SAMM50
RACGAP1	RASSF2	REEP5	RINT1	RPAP1	RPP25	RSF1	SAP130
RACK1	RASSF3	REEP6	RIOK2	RPAP3	RPP25L	RSPH14	SAP18
RAD1	RASSF5	REL	RIOK3	RPE65	RPP38	RSPH3	SAP25
RAD18	RASSF6	RELA	RIPK1	RPF2	RPRD1A	RSPO3	SAP30BP
RAD21	RASSF7	RELB	RIPK2	RPGR	RPRD1B	RSRC1	SAR1A
RAD23A	RASSF8	REPIN1	RIPK3	RPGRIP1	RPRD2	RSRP1	SARG
RAD23B	RASSF9	REPS1	RIPK4	RPGRIP1L	RPRM	RSU1	SARM1
RAD51	RB1	REPS2	RIT1	RPH3A	RPS10	RTF1	SARNP
RAD51D	RB1CC1	RER1	RLIM	RPIA	RPS11	RTKN	SART1
RAD52	RBAK	RERE	RMDN2	RPL10	RPS13	RTKN2	SASS6
RAD54L2	RBBP4	RET	RMDN3	RPL10A	RPS14	RTN3	SAT1
RAE1	RBBP6	REXO1L1	RMND5A	RPL11	RPS15	RTN4	SATB1
RAF1	RBBP7	P	RMND5B	RPL12	RPS15A	RTP2	SAV1
RAI1	RBBP8	RFC2	RNASE2	RPL13	RPS16	RTP5	SAXO1
RAI14	RBBP8NL	RFC3	RNASE6	RPL13A	RPS17	RUBCN	SBF1
RAI2	RBCK1	RFC4	RNASEH2	RPL14	RPS18	RUBCNL	SBF2
RALA	RBFA	RFWD3	A	RPL15	RPS19	RUNDC3	SBSN
RALB	RBF0X2	RFX6	RNF10	RPL17	RPS2	A	SCAMP1
RALBP1	RBL1	RFXAP	RNF11	RPL18	RPS20	RUNX1T1	SCAMP3
RALGAPB	RBM10	RGCC	RNF126	RPL18A	RPS21	RUNX3	SCAMP5
RALGDS	RBM12B	RGPD5	RNF139	RPL19	RPS23	RUSC1	SCAND1
RALGPS1	RBM14	RGS1	RNF14	RPL21	RPS25	RUSC1-	SCARA3
RALGPS2	RBM22	RGS10	RNF146	RPL22	RPS26	AS1	SCARF2
RALYL	RBM25	RGS12	RNF166	RPL23	RPS26P1	RUSC2	SCFD1
RAN	RBM26	RGS14	RNF167	RPL23A	1	RUVBL1	SCGN
RANBP1	RBM27	RGS17	RNF169	RPL24	RPS27	RUVBL2	SCHIP1
RANBP10	RBM3	RGS2	RNF170	RPL26	RPS27A	RWDD2B	SCLT1
RANBP2	RBM39	RGS20	RNF183	RPL27	RPS27L	RWDD3	SCMH1
RANBP9	RBM4	RGS22	RNF19A	RPL27A	RPS28	RXFP1	SCML1
RANGAP1	RBM42	RGS3	RNF20	RPL28	RPS29	RXRA	SCML2
RANGRF	RBM47	RGS4	RNF219	RPL3	RPS3	RXRB	SCN2A
RAP1A	RBM48	RGS9	RNF220	RPL30	RPS3A	RXRG	SCN5A
RAP1B	RBM5	RHBDL1	RNF31	RPL31	RPS4X	RYBP	SCNM1
RAP1GAP	RBM6	RHNO1	RNF32	RPL34	RPS4Y1	RYDEN	SCNN1A
RAP1GDS	RBM8A	RHO	RNF38	RPL35	RPS5	RYR1	SCNN1B
1	RBMX	RHOA	RNF4	RPL35A	RPS6	RYR2	SCNN1G
RAP2A	RBMXL1	RHOBTB2	RNF40	RPL36	RPS6KA1	S100A1	SCO1
RAP2B	RBMYL1A	RHOG	RNF41	RPL36A	RPS6KA3	S100A11	SCO2
RAPGEF1	1	RHOT1	RNF5	RPL36AL	RPS6KA5	S100A14	SCOC
RAPGEF2	RBPJ	RHOT2	RNF7	RPL38	RPS6KB1	S100A2	SCP2
RAPH1	RBPMS	RHOU	RNF8	RPL39	RPS6KB2	S100A3	SCRIB
RAPSN	RBPMS2	RHOV	RNPC3	RPL4	RPS7	S100A4	SCRN3



SCTR	SERP1	SH2D4A	SIRT2	SLC30A1	SLX4	SNCB	SORCS3
SCYL1	SERP2	SH2D5	SIRT3	0	SMAD1	SND1	SORD
SCYL2	SERPINA1	SH3BGR	SIVA1	SLC30A2	SMAD2	SNF8	SORL1
SDC2	SERPINA1	SH3BGRL	SKA1	SLC30A3	SMAD3	SNPH	SORT1
SDC3	0	SH3BGRL	SKA3	SLC30A4	SMAD4	SNRNP20	SOS1
SDC4	SERPINA4	3	SKAP1	SLC32A1	SMAD5	0	SOS2
SDCBP	SERPINA5	SH3BP2	SKIL	SLC33A1	SMAD7	SNRNP25	SOST
SDCBP2	SERPINB1	SH3BP4	SKIV2L2	SLC34A2	SMAD9	SNRNP35	SOX10
SDCCAG8	3	SH3BP5	SKP1	SLC35E1	SMAGP	SNRNP70	SOX13
SDF2L1	SERPINB4	SH3BP5L	SKP2	SLC35F6	SMAP	SNRPA1	SOX14
SDF4	SERPINB5	SH3D19	SLA	SLC38A1	SMAP1	SNRPB	SOX17
SDHA	SERPINE2	SH3D21	SLA2	SLC38A1	SMAP2	SNRPB2	SOX18
SDHC	SERTAD1	SH3GL1	SLAIN1	0	SMARCA	SNRPC	SOX2
SDK1	SERTAD3	SH3GL2	SLC12A2	SLC38A2	2	SNRPD1	SOX5
SDK2	SERTAD4	SH3GL3	SLC12A7	SLC38A5	SMARCA	SNRPD2	SOX7
SEC13	SES2	SH3GLB1	SLC12A9	SLC38A9	4	SNRPF	SP1
SEC16A	SESTD1	SH3GLB2	SLC13A4	SLC39A1	SMARCB	SNRPN	SP100
SEC22A	SET	SH3KBP1	SLC14A2	3	1	SNTA1	SP140L
SEC22B	SETD1A	SH3PXD2	SLC15A5	SLC39A1	SMARCC	SNTB1	SP2
SEC23A	SETD7	A	SLC16A1	4	1	SNTB2	SP7
SEC24B	SETDB1	SH3RF1	SLC16A3	SLC39A7	SMARCC	SNTG2	SPA17
SEC24C	SETX	SH3RF2	SLC16A6	SLC3A2	2	SNU13	SPAG5
SEC24D	SEZ6	SH3RF3	SLC16A7	SLC40A1	SMARCD	SNW1	SPAG8
SEC61A1	SF1	SHANK1	SLC17A5	SLC41A1	1	SNX1	SPAG9
SEC61A2	SF3A1	SHANK2	SLC1A3	SLC43A3	SMARCD	SNX10	SPANXN2
SEC61B	SF3A2	SHANK3	SLC1A5	SLC45A1	2	SNX11	SPARCL1
SEC62	SF3A3	SHARPIN	SLC20A1	SLC4A1	SMARCE1	SNX12	SPATA13
SEC63	SF3B1	SHC1	SLC22A2	SLC4A1A	SMC2	SNX15	SPATA16
SEH1L	SF3B2	SHC2	SLC22A2	P	SMC3	SNX17	SPATA17
SELENON	SF3B3	SHC3	3	SLC4A2	SMC4	SNX18	SPATA2
SELENOP	SF3B4	SHC4	SLC24A1	SLC4A4	SMC6	SNX19	SPATA20
SELENOV	SFI1	SHD	SLC25A1	SLC4A7	SMCP	SNX2	SPATA24
SEM1	SFMBT1	SHH	SLC25A1	SLC5A1	SMG1	SNX22	SPATA2L
SEMA3B	SFN	SHISA5	0	SLC6A12	SMIM1	SNX24	SPATA31
SEMA4C	SFPQ	SHISA6	SLC25A1	SLC6A2	SMIM3	SNX27	E1
SEMA4G	SFR1	SHKBP1	1	SLC6A3	SMIM5	SNX3	SPATA8
SEMA7A	SFRP4	SHOC2	SLC25A1	SLC6A4	SMN1	SNX31	SPATC1L
SENP1	SFXN1	SHOX2	3	SLC6A9	SMNDC1	SNX33	SPATS1
SENP2	SFXN3	SHPK	SLC25A1	SLC7A14	SMO	SNX5	SPCS2
SENP3	SFXN4	SHROOM	8	SLC7A5	SMPD2	SNX6	SPDYA
SEPT1	SGF29	2	SLC25A2	SLC8A1	SMR3B	SNX8	SPDYC
SEPT10	SGK1	SHROOM	2	SLC9A3R	SMS	SNX9	SPDYE4
SEPT11	SGK223	3	SLC25A2	1	SMU1	SOAT1	SPECC1
SEPT12	SGK3	SIAH1	7	SLC9A3R	SMURF1	SOAT2	SPECC1L
SEPT14	SGO2	SIAH2	SLC25A3	2	SMURF2	SOC51	SPEG
SEPT2	SGPL1	SIGLEC9	SLC25A3	SLC9A9	SMYD1	SOC53	SPERT
SEPT3	SGSM2	SIGMAR1	1	SLCO1C1	SMYD2	SOC56	SPG11
SEPT5	SGTA	SIK2	SLC25A3	SLCO4A1	SNAI1	SOC57	SPG20
SEPT6	SGTB	SIKE1	6	SLFN5	SNAP23	SOD1	SPG21
SEPT7	SH2B1	SIM2	SLC25A4	SLIRP	SNAP25	SOD2	SPHK1
SEPT8	SH2B3	SIN3A	SLC25A5	SLITRK1	SNAP29	SOD3	SPHK2
SEPT9	SH2D1A	SIPA1	SLC25A6	SLK	SNAP47	SOGA1	SPICE1
SERAC1	SH2D1B	SIPA1L1	SLC27A4	SLMAP	SNAPC5	SOHLH1	SPIN1
SERBP1	SH2D2A	SIPA1L3	SLC29A1	SLPI	SNAPIN	SORBS1	SPIN3
SERINC1	SH2D3A	SIRPB1	SLC2A1	SLTM	SNCA	SORBS2	SPINK2
SERINC3	SH2D3C	SIRT1		SLX1A	SNCAIP	SORBS3	SPINT2

SPIRE1	SRSF5	STK38L	SUSD2	TACC2	TCAP	TFB1M	TLE3
SPNS1	SRSF9	STK39	SUV39H1	TACC3	TCEA2	TFCP2	TLK1
SPOCD1	SS18	STK4	SUV39H2	TADA3	TCEAL5	TFDP1	TLN1
SPOCK1	SS18L1	STK40	SV2A	TAF1	TCEANC	TFE3	TLN2
SPOP	SS18L2	STMN1	SV2B	TAF12	TCEANC2	TFF1	TLR2
SPRED1	SSB	STN1	SVIL	TAF15	TCERG1	TFG	TLR3
SPRED2	SSBP1	STOM	SVOP	TAF1D	TCF12	TFIP11	TLR4
SPRN	SSBP2	STOML2	SYBU	TAF1L	TCF20	TFPT	TLX3
SPRR1A	SSC5D	STON2	SYCE1	TAF2	TCF25	TFRC	TM4SF1
SPRR2A	SSFA2	STRADB	SYCE2	TAF4	TCF4	TGFA	TM9SF1
SPRY1	SSH1	STRAP	SYCE3	TAF5	TCF7	TGFB1	TM9SF4
SPRY2	SSH2	STRBP	SYDE1	TAF6L	TCF7L2	TGFB2	TMBIM6
SPRY3	SSNA1	STRIP1	SYK	TAF7	TCHP	TGFBR1	TMC6
SPRY4	SSR1	STRIP2	SYN1	TAF7L	TCIRG1	TGFBR2	TMCC1
SPSB3	SSR3	STRN	SYN2	TAF8	TCL1A	TGFBR3	TMCO1
SPTA1	SSR4	STRN3	SYN3	TAF9	TCOF1	TGFBRAP	TMCO3
SPTAN1	SSRP1	STRN4	SYNC	TAGLN	TCP1	1	TMED10
SPTB	SSSCA1	STT3A	SYNCRIP	TAGLN2	TCRB	TGIF1	TMED2
SPTBN1	SSTR3	STT3B	SYNDIG1	TANC1	TCTE1	TGM2	TMEFF1
SPTBN2	SSX2IP	STUB1	SYNE1	TANC2	TCTEX1D	TGOLN2	TMEM10
SPTBN4	ST13	STX10	SYNE2	TANK	2	TGS1	0
SPTLC1	ST14	STX11	SYNE4	TAP2	TCTEX1D	TH	TMEM10
SPZ1	ST5	STX12	SYNGAP1	TARBP2	4	THAP11	2
SQSTM1	STAC	STX16	SYNGR1	TAT	TCTN1	THAP4	TMEM10
SRA1	STAM	STX17	SYNGR2	TBC1D1	TCTN2	THAP6	6A
SRC	STAM2	STX18	SYNGR3	TBC1D14	TCTN3	THAP7	TMEM10
SRCAP	STAMBP	STX19	SYNJ1	TBC1D15	TDG	THEM4	6C
SRCIN1	STAMBPL	STX1A	SYNJ2	TBC1D17	TDO2	THOC1	TMEM10
SREBF2	1	STX1B	SYNM	TBC1D22	TDP2	THOC2	8
SREK1	STAP1	STX2	SYNPO	B	TDRD1	THOC6	TMEM11
SREK1IP1	STAP2	STX3	SYNPO2	TBC1D25	TDRD3	THOP1	TMEM11
SRGAP2	STARD13	STX4	SYNPO2L	TBC1D30	TDRKH	THRAP3	5
SRGAP2C	STARD3	STX5	SYNPR	TBC1D31	TEAD1	THRSP	TMEM12
SRGAP3	STARD3N	STX6	SYP	TBC1D4	TEAD2	TIA1	0A
SRI	L	STX7	SYPL1	TBC1D5	TEAD3	TIAL1	TMEM12
SRL	STARD8	STX8	SYPL2	TBC1D7	TEC	TIAM1	1
SRP14	STAT1	STXBP1	SYT1	TBC1D8B	TECR	TIAM2	TMEM12
SRP19	STAT2	STXBP5	SYT11	TBC1D9B	TEFM	TICAM1	8
SRP68	STAT3	STXBP5L	SYT16	TBCA	TEK	TICAM2	TMEM13
SRP72	STAT5A	STYK1	SYT17	TBK1	TEKT4	TIE1	1
SRP9	STAT5B	SUB1	SYT2	TBKBP1	TELO2	TIGD1	TMEM13
SRPK1	STAU1	SUDS3	SYT4	TBL1X	TENM2	TIGIT	2C
SRPK2	STAU2	SUFU	SYT5	TBL1XR1	TEPSIN	TIMM13	TMEM13
SRPK3	STC2	SUGT1	SYT6	TBL2	TERF1	TIMM17	2D
SRPRB	STIL	SULT4A1	SYT7	TBL3	TERF2IP	A	TMEM14
SRPX2	STIP1	SUMF1	SYTL1	TBP	TERT	TIMM23	B
SRR	STK11	SUMF2	SYTL2	TBPL1	TES	TIMM50	TMEM14
SRRM1	STK16	SUMO1	SYTL3	TBR1	TESK2	TIMMDC	C
SRRM2	STK19	SUMO2	SYTL4	TBRG1	TEX101	1	TMEM15
SRRM4	STK24	SUN1	SYTL5	TBRG4	TEX11	TIMP2	9
SRRT	STK25	SUN2	SYVN1	TBX15	TEX28	TINF2	TMEM16
SRSF1	STK26	SUOX	T-ENOL	TBX18	TEX33	TIPRL	1A
SRSF10	STK3	SUPT7L	TAB1	TBX3	TEX37	TIRAP	TMEM16
SRSF11	STK33	SURF2	TAB2	TBX5	TFAP2A	TJP2	8
SRSF12	STK36	SURF4	TAB3	TBXA2R	TFAP2C	TK1	TMEM17
SRSF4	STK38	SUSD1	TAC3	TCAF1	TFAP2D	TLE1	

TMEM18 6	TMX4 TNF	TOR1AIP 1	TRAPPC9 TRDMT1	TSEN2 TSG101	TUBB8 TUBG1	UBE2E2 UBE2E3	URB1- AS1
TMEM19 0	TNFAIP1 TNFAIP3	TOR1AIP 2	TRHDE TRIB2	TSGA10 TSGA10IP	TUBGCP2 TUBGCP6	UBE2G2 UBE2H	URB2 URGCP
TMEM19 9	TNFAIP8L 2	TOX TOX2	TRIM16 TRIM22	TSHR TSHZ2	TUFM TUFT1	UBE2I UBE2J1	URI1 UROD
TMEM20 1	TNFRSF1 0A	TOX3 TOX4	TRIM23 TRIM25	TSKS TSLP	TULP1 TULP3	UBE2K UBE2L3	USE1 USF1
TMEM20 3	TNFRSF1 0B	TP53 TP53BP1	TRIM27 TRIM28	TSN TSNARE1	TULP4 TUSC3	UBE2L6 UBE2M	USF2 USH1C
TMEM21 6	TNFRSF1 0D	TP53BP2 TP53RK	TRIM29 TRIM32	TSNAX TSPAN18	TUSC5 TWF1	UBE2N UBE2S	USHBP1 USMG5
TMEM21 8	TNFRSF1 4	TP53TG3 TP63	TRIM33 TRIM37	TSPAN7 TSPOAP1	TWF2 TWISTNB	UBE2U UBE2V1	USO1 USP1
TMEM22 2	TNFRSF1 A	TP73 TPBG	TRIM38 TRIM39	TSPYL TSPYL1	TXK TXLNA	UBE2V2 UBE2W	USP11 USP13
TMEM22 5	TNFRSF1 B	TPD52 TPD52L2	TRIM4 TRIM41	TSPYL2 TSR2	TXLNB TXN	UBE2Z UBE3A	USP14 USP15
TMEM23 0	TNFRSF2 1	TPGS2 TPI1	TRIM42 TRIM44	TSSK3 TSSK6	TXN2 TXNDC12	UBE3B UBE3C	USP18 USP19
TMEM23 1	TNFSF10 TNIK	TPM1 TPM2	TRIM45 TRIM46	TSTD2 TTC1	TXNDC15 TXNDC17	UBE4B UBN1	USP2 USP20
TMEM23 7	TNIP1 TNIP3	TPM3 TPM4	TRIM51 TRIM54	TTC19 TTC23	TXNDC5 TXNDC9	UBQLN1 UBQLN2	USP21 USP22
TMEM25 4	TNK1 TNK2	TPPP TPR	TRIM56 TRIM59	TTC23L TTC3	TXNIP TXNL1	UBQLN4 UBR1	USP24 USP3
TMEM33	TNKS	TPRG1L	TRIM63	TTC4	TXNL4A	UBR5	USP32
TMEM41 A	TNKS2 TNMD	TPRN TPT1	TRIM73 TRIM8	TTC5 TTC7B	TXNL4B TYK2	UBTF UBXN1	USP4 USP42
TMEM43	TNNT1	TPTE	TRIM9	TTC9C	TYMS	UBXN6	USP43
TMEM44	TNNT3	TPX2	TRIML2	TTK	TYMSOS	UBXN7	USP45
TMEM54	TNPO1	TRABD	TRIO	TTLL10	TYRO3	UCHL1	USP46
TMEM57	TNPO2	TRADD	TRIOBP	TTLL11	TYRP1	UCHL3	USP6NL
TMEM59	TNPO3	TRAF1	TRIP10	TTLL5	TYW3	UCHL5	USP7
TMEM60	TNR	TRAF2	TRIP12	TTLL6	UACA	UFD1L	USP8
TMEM63 B	TNRC18 TNRC6A	TRAF3 TRAF3IP1	TRIP13 TRIP4	TTLL7 TTN	UAP1 UBA1	UFM1 UFSP1	USPL1 UST
TMEM67	TNRC6B	TRAF3IP2	TRIP6	TTPA	UBA2	UGT2B7	UTP14A
TMEM86 A	TNS2 TNS3	TRAF3IP3 TRAF4	TRMO TRMT112	TTR TTYH2	UBA52 UBA6	UHRF1BP 1	UTP3 UTP4
TMEM87 A	TNS4 TOB1	TRAF5 TRAF6	TRMT2A TRMT6	TU3A TUBA1A	UBAC1 UBAC2	UHRF2 UIMC1	UTRN UVRAG
TMEM9	TOB2	TRAFD1	TROVE2	TUBA1B	UBAP2L	ULK1	UXT
TMEM94	TOE1	TRAIP	TRPC4AP	TUBA1C	UBASH3A	UMPS	VAC14
TMEM99	TOLLIP	TRAP1	TRPM6	TUBA3C	UBASH3B	UNC119	VAMP1
TMIGD1	TOM1	TRAPPC1	TRPM7	TUBA4A	UBB	UNC13A	VAMP2
TMOD1	TOM1L1	TRAPPC1	TRPS1	TUBA8	UBC	UNC13B	VAMP3
TMOD3	TOMM20	0	TRPV4	TUBAL3	UBD	UNC45A	VAMP4
TMPO	TOMM22	TRAPPC1	TRPV5	TUBB	UBE2A	UNC5C	VAMP5
TMPRSS2	TOMM40	3	TRPV6	TUBB1	UBE2B	UNC93B1	VAMP7
TMTC1	TOMM70	TRAPPC2	TRRAP	TUBB2A	UBE2D1	UNKL	VAMP8
TMTC3	TONSL	L	TRUB2	TUBB2B	UBE2D2	UPF1	VANGL1
TMUB1	TOP1	TRAPPC3	TSACC	TUBB3	UBE2D3	UPF3A	VANGL2
TMX1	TOP2A	TRAPPC4	TSC2	TUBB4A	UBE2D4	UPK1B	VAPA
TMX2	TOPBP1	TRAPPC6	TSC22D1	TUBB4B	UBE2DNL	UQCRC2	VAPB
TMX3	TOR1A	A	TSC22D4	TUBB6	UBE2E1	UQCRCQ	VARS

VARS2	VTI1A	WIPF1	YTHDF3	ZCCHC12	ZMYND1	ZNF341	ZNF687
VASH2	VTI1B	WIPI2	YWHAB	ZCCHC14	9	ZNF35	ZNF691
VASN	VTN	WLS	YWHAE	ZCCHC17	ZMYND8	ZNF362	ZNF696
VASP	VWA5B2	WNK1	YWHAG	ZCCHC6	ZNF10	ZNF365	ZNF697
VAV1	VWA9	WNK2	YWHAH	ZCCHC7	ZNF106	ZNF366	ZNF707
VAV2	VWC2	WNT3A	YWHAQ	ZCCHC8	ZNF12	ZNF385C	ZNF71
VAX1	VWC2L	WNT4	YWHAZ	ZCCHC9	ZNF124	ZNF408	ZNF740
VCAM1	VWCE	WNT7A	YY1	ZDHHHC12	ZNF133	ZNF410	ZNF746
VCL	VWF	WNT7B	YY1AP1	ZDHHHC17	ZNF135	ZNF414	ZNF750
VCP	WAC	WRAP73	ZAK	ZDHHHC5	ZNF136	ZNF417	ZNF76
VCPIP1	WAPL	WSB1	ZAP70	ZER1	ZNF148	ZNF438	ZNF764
VDAC1	WAS	WT1	ZBED1	ZFAND5	ZNF16	ZNF440	ZNF765
VDAC2	WASF1	WWC1	ZBTB1	ZFAND6	ZNF165	ZNF446	ZNF766
VDR	WASF2	WVOX	ZBTB11	ZFC3H1	ZNF17	ZNF451	ZNF768
VEGFA	WASF3	WWP1	ZBTB12	ZFHX3	ZNF174	ZNF462	ZNF77
VEGFD	WASH2P	WWP2	ZBTB14	ZFP1	ZNF175	ZNF479	ZNF774
VENTX	WASHC1	WWTR1	ZBTB16	ZFP2	ZNF180	ZNF488	ZNF784
VEZF1	WASHC3	XAGE2	ZBTB2	ZFP36	ZNF189	ZNF490	ZNF785
VGF	WASL	XBP1	ZBTB20	ZFP42	ZNF197	ZNF496	ZNF792
VGLL3	WBP1	XIAP	ZBTB21	ZFP91	ZNF20	ZNF497	ZNF827
VHL	WBP11	XIRP2	ZBTB22	ZFPL1	ZNF200	ZNF509	ZNF830
VIM	WBP2	XPA	ZBTB24	ZFPM1	ZNF205	ZNF510	ZNF837
VIPR1	WBP4	XPNPEP1	ZBTB26	ZFR	ZNF207	ZNF512B	ZNF844
VKORC1	WDCP	XPO1	ZBTB32	ZFYVE1	ZNF211	ZNF518A	ZNF91
VMA21	WDFY3	XPO5	ZBTB33	ZFYVE16	ZNF217	ZNF524	ZNFX1
VMAC	WDHD1	XPO6	ZBTB38	ZFYVE19	ZNF219	ZNF526	ZNHIT3
VOPP1	WDR1	XPO7	ZBTB4	ZFYVE21	ZNF223	ZNF532	ZNHIT6
VPRBP	WDR19	XPOT	ZBTB40	ZFYVE28	ZNF227	ZNF544	ZNRD1
VPS11	WDR20	XPR1	ZBTB42	ZFYVE9	ZNF23	ZNF563	ZNRF1
VPS13A	WDR26	XRCC1	ZBTB43	ZG16	ZNF230	ZNF564	ZNRF2
VPS25	WDR33	XRCC3	ZBTB48	ZGPAT	ZNF233	ZNF568	ZP2
VPS26A	WDR45	XRCC5	ZBTB49	ZHX1	ZNF234	ZNF572	ZRANB1
VPS26B	WDR48	XRCC6	ZBTB5	ZIC1	ZNF24	ZNF575	ZRANB2
VPS29	WDR5	XRN1	ZBTB6	ZIC3	ZNF250	ZNF576	ZSCAN1
VPS33B	WDR6	XRN2	ZBTB7A	ZIC5	ZNF260	ZNF579	ZSCAN12
VPS35	WDR76	YAP1	ZBTB7B	ZKSCAN8	ZNF264	ZNF580	ZSCAN21
VPS37B	WDR77	YARS	ZBTB8A	ZMAT2	ZNF267	ZNF581	ZSCAN23
VPS37C	WDR81	YBX1	ZBTB9	ZMAT3	ZNF273	ZNF587	ZSCAN26
VPS4A	WDR82	YBX3	ZC2HC1A	ZMIZ1	ZNF276	ZNF592	ZSCAN30
VPSS0	WDR91	YEATS4	ZC2HC1C	ZMIZ2	ZNF280A	ZNF593	ZSCAN9
VPSS1	WDR92	YES1	ZC3H10	ZMPSTE2	ZNF281	ZNF597	ZSWIM1
VPSS2	WDYHV1	YIF1A	ZC3H12A	4	ZNF286A	ZNF599	ZSWIM3
VPSS3	WEE1	YIPF5	ZC3H14	ZMYM1	ZNF3	ZNF622	ZSWIM6
VPSS4	WFDC1	YLPM1	ZC3H18	ZMYM2	ZNF317	ZNF624	ZWINT
VPS9D1	WFDC2	YME1L1	ZC3H3	ZMYM3	ZNF319	ZNF638	ZXDC
VRK2	WFDC3	YOD1	ZC3H4	ZMYM5	ZNF326	ZNF639	ZYX
VRTN	WHAMM	YPEL2	ZC3HAV1	ZMYND1	ZNF329	ZNF648	ZZZ3
VSTM4	P3	YPEL5	ZC3HC1	1	ZNF330	ZNF658B	
VSX2	WHRN	YTHDC1	ZC4H2	ZMYND1	ZNF333	ZNF669	
VTA1	WIF1	YTHDF1	ZCCHC10	2	ZNF33B	ZNF670	